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Cullin RING ubiquitin ligases (CRLs) constitute the largest family 
of cellular ubiquitin ligases with diverse cellular functions. CRLs comprise 
of seven homologous cullin-based complexes. The cullin proteins serve as 
scaffolds for the assembly of the RING protein and substrate receptor 
subunits. CRLs are activated via the conjugation with the ubiquitin-like 
protein Nedd8 onto the cullin scaffold protein. Cullin neddylation leads to a 
conformational change in the cullin C-terminus/Rbx1 structure that is 
essential for facilitating the ubiquitin transfer onto the substrate. However, 
cullin neddylation is not permanent. It is reversed via the COP9 Signalosome 
(CSN). Although CSN-mediated cullin deneddylation inhibits CRL activity 
in vitro, it is important for CRL function in vivo. It has been suggested that 
cycles of neddylation and deneddylation are essential to regulate CRL 
activity in vivo. However, the mechanism through which CSN regulates CRL 
activity in vivo remains incompletely understood. In this study, we used a 
mammalian cellular system to study the mechanisms through which CRL 
activity is regulated by CSN and Nedd8 in vivo. We confirmed that the 
Nedd8 modification of cullin proteins is highly dynamic. We showed that 
CSN-mediated cullin deneddylation is not directly coupled to substrate 
polyubiquitination. We found that the CSN complex binds preferentially to 
the active form of CRLs that is in the neddylation-induced conformation. We 
propose that the binding of CSN to active CRLs may be important to recruit 
CSN-associated proteins that are essential to regulate CRL activity. CSN 
would subsequently mediate cullin deneddylation to promote its own 
! xi!
dissociation from the cullin complex to resume the cycle of neddylation and 
denddylation. 
It is well established that the Cullin3 (Cul3) E3 ubiquitin ligase 
exists in a dimeric form. Two different models for CRL3 dimerization have 
been proposed. Firstly, it has been suggested that the Cul3 dimer complex 
formation is indirect and mediated via BTB substrate receptor 
homodimerization. Second, two Cul3 proteins have been proposed to 
dimerize directly via interaction of the C-terminal WH-B domain. This Cul3 
dimer consists of one Nedd8-modified Cul3 and one unmodified Cul3 
protein. In this study, we provide strong evidence in favor of the first model. 
Thus, we found that that Cul3 dimerization is independent of its modification 
with Nedd8. Furthermore, we showed that Cul3 dimerization is mediated via 
the Cul3 N-terminus and not the C-terminus. In addition, our results provide 
evidence that the majority of the cellular Cul3 proteins exists in a dimeric or 
multimeric form, suggesting that Cul3 dimerization is likely to play an 
important role in promoting substrate ubiquitination.  
Finally, we tried to identify novel Skp1-Cul1-F-box (SCF) 
substrates that may be involved in cancer. We selected a number of proteins 
that contain a recognition motif for the F-box protein β-TrCP, including 
GKAP1, ACBD5 and Tulp1, for evaluation based on candidate SCF 
substrates identified by global protein stability profiling. However, we found 
that none of these proteins could be confirmed as a novel SCF substrate. 
Based on candidate SCF substrates identified by global protein stability 
profiling, Stem-loop binding protein has also been identified as a potential 
! xii!
novel SCF substrate. Stem Loop Binding Protein (SLBP) does not contain 
any apparent SCF recognition motif. SLBP is involved in the cell cycle by 
regulating the cell cycle dependent expression of histones. Our results 
provide evidence that SLBP ubiquitination is indeed regulated by the 
ubiquitin proteasome system. SLBP degradation is dependent on a functional 
Nedd8 pathway. However, we found no conclusive evidence for an 
involvement of a specific SCF complex or a different Cullin-based E3 ligase 
in the ubiquitination of the SLBP protein. Our results suggest that SLBP 
degradation is mediated through a Nedd8 dependent, but CRL independent 
mechanism. Thus, our study highlights that the Nedd8 pathway may have 
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1.0 Introduction  
 1.1 The ubiquitin proteasome system  
 The ubiquitin proteasome system (UPS) is known to play an 
essential role in almost every aspect of eukaryotic cell biology. In the late 
1970’s, the 76-amino acid ubiquitin protein was discovered (Goldstein et al., 
1975). The ubiquitin proteasome pathway was then identified in the early 
1980’s (Ciechanover et al., 1980). The UPS is important in maintaining and 
controlling the cellular homeostasis (Ciechanover et al., 1980). Thus, the 
UPS mediates constitutive degradation of cellular proteins to avoid the 
accumulation of damaged proteins. The UPS can also specifically mediate 
the degradation of damaged proteins. For instance, misfolded or damaged 
proteins from the endoplasmic reticulum (ER) are rapidly destroyed by the 
UPS (Plemper and Wolf, 1999). In addition, the UPS mediates proteolysis of 
many short-lived regulatory proteins such as transcription factors, cell cycle 
regulatory proteins and proteins involved in DNA damage repair (Hershko 
and Ciechanover, 1998). Thus, the ubiquitin proteasome system plays an 
important role in many cellular functions from transcription to cell cycle 
progression, cellular signaling and immune response (Hershko and 
Ciechanover, 1998). 
 UPS deregulation has been implicated in the development of 
numerous diseases such as autoimmune, viral and neurodegenerative 
diseases as well as cancer (Schwartz and Ciechanover, 1999). In cancer, 
deregulation of the UPS generally results in increased degradation of tumor 
suppressors or reduced turnover of oncoproteins. For instance, the mouse 
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double minute-2 protein (Mdm2) oncoprotein functions as an E3 ubiquitin 
ligase to target the p53 tumor suppressor protein for proteasome dependent 
degradation. Increased levels of Mdm2 are known to inhibit the cell cycle 
arrest function of p53 (Reviewed in Levine and Oren, 2009). Although a 
wealth of knowledge has been built on the correlation between the regulation 
of the UPS and the development of certain diseases, the pathways leading to 
UPS malfunction in many of these pathological disorders are still unknown. 
Therefore, it is important to provide more insight into the function of the 
UPS and the mechanisms through which the UPS is deregulated in human 
disease.  
 In recent years, the UPS has been recognized as potential 
therapeutic target in cancer. The most notable therapeutic agent that is 
currently in use for cancer therapy is the proteasome inhibitor bortezomib 
(Velcade; Millennium Pharmaceuticals). Bortezomib was approved by the 
US Food and Drug Administration as a therapeutic drug to treat multiple 
myeloma and mantle cell lymphoma patients (Richardson et al., 2005). In 
multiple myeloma, Bortezomib treatment has been shown to inhibit the 
degradation of unfolded ER proteins and induces the intracellular unfolded 
protein response (UPR). Hence, this results in the induction of apoptosis. 
Bortezomib also targets the nuclear factor-kappa B (NFκB) pathway in 
multiple myeloma cells. It blocks the degradation of inhibitor of kappa B 
alpha (IκBα) and consequently abrogates the NFκB transcriptional activity. 
As a result, the functions of NFκB, including cell invasion, proliferation, and 
survival are inhibited (Yang et al, 2008; Markovina et al, 2008).  Bortezomib 
has proved to be a potential and useful cancer therapeutic agent in multiple 
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myeloma. Bortezomib has also been reported to be effective in other cancers, 
including pancreas, colon, breast, lung, as well as diffuse large B cell 
lymphomas in mouse models (Marten et al., 2008, Shanker et al, 2008, 
Richardson et al, 2006). However, one frequent clinical problem is the 
development of bortezomib resistance. Therefore, therapeutic agents are 
currently being developed to target specific E3 ubiquitin ligases. 
  One example of a therapeutic agent that targets the E3 ubiquitin 
ligase specifically is the potent and selective inhibitor of the Nedd8 
activating E1 enzyme (NAE), MLN4924 (Millennium Pharmaceutical). This 
drug inhibits the degradation of cullin E3 ubiquitin ligases specifically by 
preventing the cullin neddylation.  MLN4924 has been shown to inhibit the 
growth of numerous tumors, such as lung, breast and pancreas cancer as well 
as diffuse large B cell lymphoma (Soucy et al., 2009). MLN4924 has also 




 The UPS can be divided into two distinct phases: ubiquitin 
conjugation (ubiquitination) and proteasomal degradation. Protein 
ubiquitination is a post-translational modification, which results in the 
conjugation of the 76 amino acid protein ubiquitin onto a target protein in a 
catalytic cascade of three enzymes (Wilkinson et al., 1980). The three 
enzymes that are involved in the ubiquitination process are ubiquitin 
activating enzyme (E1), ubiquitin conjugating enzyme (E2) and ubiquitin 
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ligating enzyme (E3) (Hershko and Ciechanover, 1998). In the first step, the 
E1 enzyme adenylates the Ubiquitin C–terminus and forms a thioester 
linkage between a C-terminal glycine of ubiquitin and a cysteine residue on 
the E1 catalytic site in an ATP dependent manner. The activated ubiquitin is 
then transferred to one of the several E2 conjugating enzymes and also forms 
a thioester bond between the E2 active-site cysteine and the activated 
ubiquitin. Subsequently, with the collaboration of an E3 ligase, the activated 
ubiquitin is then transferred from the ubiquitin-charged E2 enzyme onto 
lysines of the substrate protein. As a result, an isopeptide bond between the 
C-terminal glycine of ubiquitin and the terminal amino group of the target 
lysine is formed. Reiteration of this catalytic cycle assembles a polyubiquitin 
chain where additional ubiquitin polypeptides are conjugated to any of the 
seven lysines residues of the ubiquitin molecule, thus leading to the 
formation of high molecular weight chains of ubiquitin attached to the target 
protein.  
 
                         
Figure 1.1 Ubiquitination. Ubiquitin (Ub) is activated by conjugating to 
ubiquitin E1 enzyme in an ATP-dependent manner. Subsequently, the 
ubiquitin is transferred to ubiquitin E2 enzyme. With the assistance of an E3 
ubiquitin ligase, ubiquitin is then transferred from E2 to target substrate. 
Reiteration of this catalytic cycle assembles a polyubiquitin chain on the 
target substrate. The polyubiquitin chain target substrate is recognized and 
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degraded by the 26S proteasome.  
 
 In humans, there are two E1 enzymes, at least 38 E2 enzymes and 
600-1000 E3 enzymes (Schulman and Harper, 2009). The E3 ligases play an 
important role in conferring the substrate specificity. They can target an 
enormous range of substrates for ubiquitination. The E2 and E3 enzymes can 
mediate different ubiquitin modifications, which lead to different functional 
consequences (Yu, H., et al., 1996). For instance, conjugation of a single 
ubiquitin molecule on a particular substrate (monoubiquitination) has been 
reported to regulate DNA repair, receptor endocytosis and lysosomal 
trafficking (Haglund et al., 2003; Hicke and Dunn, 2003). The ubiquitin 
molecule on the target substrate can be extended through isopeptide bonds 
between ubiquitin lysine amino acids and this generates a polyubiquitin 
chain (polyubiquitination). Different types of polyubiquitin chains can be 
formed due to the seven potential acceptor lysine residues in ubiquitin. 
Different linkages in a polyubiquitin chain lead to specific outcomes 
(reviewed in Pickart and Fushman, 2004). For instance, Lys48-linked 
ubiquitin chains have been shown to target proteins for 26S proteasome 
dependent degradation (reviewed by Ye and Rape, 2009). Lys11-linked 
polyubiquitin chains, which are synthesized by the anaphase-promoting 
complex (APC/C), are also targeted for proteasome mediated degradation 
(Jin et al, 2008). In contrast, Lys63-linked polyubiquitinaion is involved in 
nonproteolytic functions, such as protein trafficking, kinase/phosphatase 
activation, and DNA damage control (Hicke, L., 1999, Arnason et al., 1994, 
Spence et al., 1995, Deng et al., 2000, Strous and Govers, 1999, Chen and 
Sun, 2009). However, for other ubiquitin linkages such as Lys6-linked and 
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Lys29-linked chains, the substrates and the functional consequences remain 
unknown (reviewed by Ye and Rape, 2009).  
 
1.3 Proteasome  
 The proteasome degrades unneeded, misfolded or damaged proteins 
into short peptides via proteolysis and also recycles the ubiquitin molecules. 
Those short peptides normally contain less than ten amino acids and after 
being degraded into amino acids, they can be used for new protein synthesis. 
The proteasome only targets the proteins that are tagged with a polyubiquitin 
chain for degradation (Reviewed in Glickman and Ciechanover, 2002).  
 The 26S proteasome is a large multisubunit complex, which is 
composed of two smaller subcomponents, 20S core particle and 19S 
regulatory particle. The 20S core particle mediates substrate proteolysis 
whereas the 19S regulatory particle plays an important role in 
polyubiquitinated substrate recognition, unfolding and translocation into the 
proteolytic chamber (Nickell et al., 2009). The 19S regulatory particle can be 
further separated into two components—the lid and base (reviewed by 
Pickart and Cohen 2004). The lid consists of nine non-ATPase subunits and 
is essential for substrate deubiquitination. The base is composed of six AAA-
ATPase subunits and four non-ATPase subunits. The ATPases in the base 
mediate substrates unfolding and channel opening before translocation of 
substrate into the 20S catalytic core for proteolysis. The 20S core particle is 
in a barrel shape. The subunits within this 20S proteasome complex contain 
the catalytic protease sites, which have three peptidase activities, 
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chymotryptic, tryptic and caspase-like activities (reviewed by Pickart and 
Cohen 2004). Both ends of this 20S core particle complex are capped by the 
19S sub-complex, which controls both substrate translocation to and peptide 
release from the core (Kohler et al., 2001). 
 
1.4 E3 Ubiquitin Ligases 
The hallmark of E3 ubiquitin ligases is their involvement in targeting 
substrate proteins for 26S prosteasome dependent degradation. The E3 
ubiquitin ligases recruit the ubiquitin-charged E2 enzyme through conserved 
HECT (Homologous to E6-AP Carboxy Terminus) or RING (Really 
Interesting New Gene) domains and mediate the formation of a polyubiquitin 
chain on the substrate.  
The HECT ubiquitin ligase domain was originally found in the course 
of characterizing the mechanism of the p53 substrate ubiquitination by the 
E6-AP ubiquitin ligase in certain human papillomaviruses (HPVs) (reviewed 
in Pickart, 2001). The highly conserved C-terminus of the E6-AP protein 
contains approximately 350 amino acids which form the HECT domain. E6-
AP interacts with the E6 protein of the cancer-associated HPV types 16 and 
18, and consequently ubiquitinates the p53 tumor suppressor protein, leading 
to 26S proteasome dependent degradation of p53 (Huibregtse et al., 1995). 
All HECT E3 ligases contain a conserved catalytic cysteine to accept the 
ubiquitin molecule from the ubiquitin-charged E2 enzyme. The ubiquitin 
molecule is then being transferred directly onto a substrate lysine residue 
(Scheffner et al., 1995). 
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 The RING-type ligase has been identified in approximately 600 
human genes. RING E3 ligases contain a zinc-binding domain which 
interacts with specific E2 enzymes (Freemont, 1993). The RING E3 ligases 
also contain a substrate binding domain or they serve as a scaffold protein 
that recruits specific substrate proteins. There are numerous types of RING-
containing E3 ubiquitin ligases. One family of RING-containing E3 ligases 
that is well characterized is the Cullin RING E3 ubiquitin ligases. 
 
1.5 Cullin RING E3 Ubiquitin Ligases 
 Cullins form an evolutionarily conserved gene family. They were 
first discovered as mediators of ubiquitin dependent proteolysis of cell cycle 
regulators in both C. elegans and budding yeast [cullin homolog Cdc53 (cell 
division control protein 53)] (Kipreos et al., 1996; Mathias et al., 1996). 
Seven different Cullin proteins (Cul1 to Cul3, Cul4a, Cul4b, Cul5 and Cul7) 
have been identified in mammalians (Homo sapiens, Mus musculus and 
Rattus norvegicus) whereas the C. elegans genome encodes six cullins (cul-1 
to cul-6) and Drosophila contains five different cullin proteins (Cul1 to 
Cul5). There are five different cullins (Cul1, Cul2, Cul3A, Cul4 and Cul5) in 
Arabidopsis and three different cullin proteins [cul1, cul3, cul8 in 
Saccharomyces cerevisiae; cul1, cul3 and cul4 in Schizosaccharomyces 
pombe] have been identified in yeast (reviewed by Sarikas et al., 2011).  
 Cullin RING ligases (CRLs) are a large family of E3 ubiquitin 
ubiquitin ligases with diverse cellular functions such as regulation of the cell 
cycle, signal transduction, transcription and development. CRLs are 
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composed of several subunits, which contain one of the cullin homologs, the 
RING finger containing protein, Roc/Rbx1, the cullin homolog-specific 
adaptor and substrate recognition subunits. The cullin homologs serve as 
scaffold proteins that bind to Roc/Rbx1 via their C-terminus whereas the N-
terminus binds to different substrate recognition subunits, which only 
recognize and recruit specific substrate proteins. Large families of these 
substrate recognition subunits greatly vary the substrate specificity that can 
be ubiquitinated by individual ligases. Specific adaptor proteins recruit 
various substrate recognition subunits and bridge the binding of the 
numerous substrate recognition subunits and the cullin homologs except for 
Cul3 (Petroski and Deshaies, 2005; Bosu and Kipreos, 2008). For instance, 
in the SCF (Skp1–Cul1–F-box) ubiquitin ligase, Skp1 serves as an adaptor 
protein to bridge the binding of various F-box domain containing substrate 
recognition subunits to the Cul1 N-terminus, forming the SCF ubiquitin 
ligase (Willems, et al., 2004) (Figure 1.2). Cullin2 binds to the substrate 
recognition subunit von Hippel–Lindau (VHL) via the adaptor proteins 
elongin B and C (Lonergan, et al., 1998, Takagi, et al., 1997). In CRL4A, 
Cul4 can assemble with the adaptor protein Damage-specific DNA Binding 
protein 1 (DDB1) and a member of the DDB1 and Cul4 Associated Factor 
(DCAF) family, which serves as the substrate recognition subunit to recruit 
different substrates (Nag et al., 2001). Similar to Cul2, through the adaptor 
proteins elongin B and C, the Cul5 protein can bind to different suppressor of 
cytokine signalling (SOCS) proteins, which serve as the substrate recognition 
subunits to recognize specific substrates (Guardavaccaro and Pagano, 2004). 
For the Cul7 protein, the Fbxw8 F-box protein assembles with Cul7 to form 
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a Cul7 ubiquitin ligase. Although Cul7 binds to Skp1, this interaction is 
indirect, mediated by the Fbxw8 protein. Hence, Skp1 does not function as 
an adaptor protein in the Cul7 E3 ligase complex. Finally, Cul3 is known to 
associate with the 'Broad complex/Tramtrack/Bric-a-Brac' (BTB) family of 
proteins, which serve as substrate recognition subunits (Zollman et al., 
1994). The BTB domain of these substrate recognition subunits binds to 
Cul3 directly. Thus, in contrast to other Cullin E3 ligases, BTB proteins bind 
directly to Cul3 without the involvement of an adaptor protein. 
 All substrate recognition subunits harbor a specific substrate-
binding domain, which is of importance for substrate recruitment. The 
substrate recruitment is usually dependent on substrate posttranslational 
modifications such as phosphorylation. For instance, the p27 substrate 
protein has been shown to be phosphorylated by the cyclin E-CDK2 complex 
or the cyclin A-CDK2 complex as a prerequisite for its ubiquitination by the 
SCFSkp2 ubiquitin ligase. Phosphorylated p27 binds to Cul1 via Skp2 and 
Skp1, whereby Skp2 serves as a substrate recognition subunit (Tsvetkov, et 
al., 1999; Bloom and Pagano, 2003; Zhu et al., 2004). The cullin protein 
brings the substrate and the ubiquitin-charges E2 enzyme into a close 
proximity, thus promoting ubiquitin transfer from the E2 enzyme to the 
target substrate. The carboxyl terminus of ubiquitin is conjugated to the 
amino group of a lysine residue on the target substrate, forming an isopeptide 
bond. The catalytic cycle reiterates and assembles a polyubiquitin chain on 
the target substrate. 
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Figure 1.2 Structures and subunit organization of CRL complexes. Each 
CRL complex model contains a cullin scaffold protein (magenta), an Rbx1 
protein (green), adaptor protein (light blue), and substrate recognition subunit 
(orange). Ubiquitin-charged E2 enzyme (yellow) binds to the RING protein, 
Rbx1. Nedd8 (purple) is conjugated to a conserved lysine residue at the C-




1.6 Structural characteristics of CRLs 
 The first crystal structure of a CRL, the Cul1–Rbx1–Skp1–F boxSkp2 
complex, was reported in 2002 (Schulman et al., 2000; Zheng et al., 2002). 
In the Cul1–Rbx1–Skp1–F boxSkp2 crystal structure, the Cul1 scaffold protein 
is an elongated protein which contains a long stalk-like amino-terminal 
domain (NTD) and globular carboxy-terminal domain (CTD). The Cul1 
NTD contains three cullin repeats (CR1 to CR3) and is involved in the 
binding of the Skp1–F boxSkp2 heterodimer. The CTD consists of three 
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subdomains, 4-helix bundle (4HB), α/β and winged-helix B (WHB). The 
4HB subdomain is responsible for the Cul1 NTD interaction whereas the α/β 
subdomain is involved in the binding of the Rbx1 RING protein. For CRLs 
that are unneddylated, the WHB subdomain interacts with the RING domain 
of Rbx1. The cullin CTD and the RING protein form the catalytic core of 
these CRLs (Zheng et al., 2000, Zheng et al., 2002). 
As expected from the sequence conservation between the different 
homologs, Cul3 and Cul4a have been shown to exhibit a very similar 
structure compared to Cul1 (Zhuang et al., 2009; Ahn et al., 2011). Because 
all CRLs share a common mechanism to ubiquitinate the substrate, Cul2 and 
Cul5 are also expected to show a similar structure as Cul1. The N-terminal 
helices H2 and H5 in the cullin repeat CR1 first repeat from Cul1 to Cul5 are 
required for recruiting the corresponding adaptor protein (Reviewed in 
Sarikas et al, 2011). Mutation in these H2 and H5 helices would disrupt the 
adaptor protein binding. There are two different types of recognition folds 
that exist in different adaptor proteins. The Skp1/BTB/Pox virus and zinc 
finger (POZ) motif is present in the adaptor proteins Skp1, Elongin C and the 
BTB substrate recognition subunit protein, which are the part of the Cul1, 
Cul2, Cul3 and Cul5 E3 ligase complexes. The BPB (β-propeller) motif is 
present in the CRL4A adaptor DDB1. Recently, a crystal structure of the 
Cul3-SPOP complex has revealed that the SPOP BTB protein does not only 
bind to Cul3 via the Skp1/BTB/POZ domain. SPOP also contains a Cul3-
interacting box domain that is termed the 3-box. This 3-box motif mediates a 
Skp1/BTB/POZ domain-independent interaction between Cul3 and SPOP. 
The 3-box motif is involved in strengthening the Cul3-SPOP interaction 
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(Zhuang et al., 2009).  
To further complete the CRL structure, the adaptor protein recruits the 
substrate recognition subunits. For instance, in the Cul1 complex, the Skp1 
adaptor protein binds the Skp2 substrate recognition subunit to complete the 
SCFSkp2 complex (Zheng et al., 2002). In CRL2 and CRL5, a common 
adaptor protein, Elongin C, is shared to recruit different substrate recognition 
subunits, VHL and SOCS-box containing proteins, respectively (Lonergan, 
et al., 1998, Takagi, et al., 1997, Guardavaccaro and Pagano, 2004). In 
CRL4A, the DDB1 adaptor protein binds the DCAF substrate recognition 
subunit to form the CRL4ADCAF complex. However, in CRL3 complexes, 
there is no separate adaptor protein. The BTB substrate recognition subunit 
binds directly to Cul3 to form the CRL3 BTB complex (reviewed in Sarikas 
et al., 2011). 
  
1.7 Functions of CRLs  
1.7.1 CRL1 
 CRL1 is the most well studied member among other modular cullin-
based ubiquitin ligases. It plays an essential role in regulating the cell cycle 
progression. In Drosophila, the Cul-1 gene is required for several stages in 
the cell cycle. In mice, Cul1 gene deletion results in early embryonic 
lethality. It has been shown that C. elegans Cul1 mutants produced small and 
abnormal cells (Kipreos et al., 1996). Thus, these findings indicate that Cul1 
is critical in regulating in the early embryonic development and the cell cycle 
(Dealy et al., 1999; Wang et al., 1999).   
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  In humans, over 70 substrate-recognizing F-box proteins have been 
identified. These F-box protein substrate receptors are able to assemble into 
distinct sets of SCF. These various sets of SCF could target a large array of 
substrates that are involved in diverse biological processes such as immune 
response, signal transduction, transcription and cell cycle progression 
(reviewed in Petroski and Deshaies 2005, Jin et al., 2004). For instance, 
Skp2, one of the most well characterized F-box proteins, assembles with 
Cul1-Rbx1 to form the SCFSkp2 complex and mediates the ubiquitin-
dependent proteolysis of cyclin-CDK2 inhibitors p27 and p21. Hence, the 
SCFSkp2 complex plays an important role in controlling the mammalian cell 
cycle by regulating the activity of cell cycle dependent kinases 
(Guardavaccaro and Pagano 2006). 
 A further well-characterized F-box protein is β-TrCP, which 
assembles with Cul1-Rbx1 and Skp1 to form the SCFβ-TrCP complex. It has 
been reported that the SCFβ-TrCP complex plays an important role in the cell 
survival response, cellular proliferation and the immune response (Yaron et 
al., 1997; Winston et al., 1999). β-TrCP recognizes a conserved DSGXXS 
destruction motif in SCFβ-TrCP substrate proteins. The two serine residues in 
the motif require phosphorylation in order to be recognized by β-TrCP. One 
of the SCFβ-TrCP complex substrates, IĸBα, plays an essential role in the NF-
ĸB signaling pathway.  The NF-ĸB transcription factor complex is only able 
to enter the nucleus after IĸBα degradation. NF-ĸB subsequently activates 
specific genes that are involved in various biological processes, including 
cellular proliferation and the immune response. 
 A further important substrate of the SCFβ-TrCP E3 ligase is β-catenin 
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(Fuchs et al., 1999). β-catenin functions as transcriptional coactivator of 
TCF/LEF transcription factors. β-catenin is involved in regulating cell 
proliferation and differentiation as well as stem cell maintenance. 
Ubiquitination of β-catenin by SCFβ-TrCP is dependent on phosphorlation of 
the DSGXXS recognition motif by CK1 and GSK-3. Failure to 
phosphorylate β-catenin, due to mutations in the destruction motif or the 
scaffold proteins adenomatous polyposis coli (APC) or Axin, is associated 
with the majority of colon cancers. 
 In addition to IĸBα and β-catenin, DEPTOR has been recently 
identified as a substrate protein that can be ubiquitinated and degraded via 
the SCFβ-TrCP complex. DEPTOR functions as an inhibitor of the mammalian 
target of rapamycin (mTOR) (Zhao et al., 2011; Duan et al., 2011; Gao et al., 
2011). mTOR is a conserved serine/threonine kinase that is known to be 
involved in regulating cell growth and proliferation, cell-cylcle progression 
as well as cell survival. DEPTOR functions as a tumor suppressor and has 
been shown to be downregulated in many tumors. 
1.7.2 CRL2 and CRL5 
 Cul2 or Cul5 knockout mouse models have thus far not been 
published. In C. elegans, the Cul2 gene is important for mitotic germline 
proliferation and meiotic division II following fertilization (Feng et al., 1999; 
Liu et al., 2004). The best-characterized substrate recognition subunit of 
Cul2 in mammals is the von Hippel-Lindau (VHL) protein. Mutations in the 
VHL substrate receptor subunit cause VHL disease, which is characterized 
by the development of a number of tumors, including hemangioblastomas, 
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pheochromocytoma and renal clear cell carcinoma. The VHL substrate 
receptor subunit protein normally assembles with Cul2 via the Elongin B/C 
adaptor proteins to form a CRL2 to target the oxygen-sensing transcription 
factor hypoxia inducible factor-1 alpha (HIF-1α) for ubiquitin-dependent 
degradation (Ivan et al., 2001, Jaakkola et al., 2001). HIF-1α is an important 
mediator of the cellular and systemic response to hypoxia. In the presence of 
oxygen, prolyl hydroxylase enzymes hydroxylate specific proline residues in 
HIF-1α. Prolyl hydroxylation results in results in the binding of the CRL2VHL 
complex to HIF-1α, which then targets HIF-1α for ubiquitination and 
subsequent proteasomal degradation. Under hypoxic conditions, prolyl 
hydroxylases are inhibited. Therefore, this leads to the accumulation of HIF-
1α and an increase in the expression of proangiogenic genes such as vascular 
endothelial growth factor (VEGF).   
  In Cul5 E3 ubiquitin ligases, substrate receptor proteins 
containing a conserved SOCS-box protein bind via the Elongin B/C adaptors 
to Cul5 to form CRL5 complexes. Cul5 E3 ubiquitin ligases also regulate the 
stability of various substrate proteins via their recruitment to specific 
substrate receptor subunits. For instance, it has been shown that HIV-1 viral 
infectivity factor (Vif) is a viral protein that contains a SOCS-box and 
assembles with the Cul5 complex to ubiquitinate the antiviral factor 
APOBEC3G (A3G). This mechanism antagonizes the host anti-HIV-1 
defence (Yu et al., 2003).    
1.7.3 CRL3 
 The first organism in which the function and specific substrates of 
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the Cul3 E3 ligase were identified is C. elegans. It was shown that loss of 
Cul3 in C. elegans leads to a defect in spindle positioning and elongation in 
single-cell embryos, resulting in failed cytokinesis (Kurz et al., 2002). This 
phenotype is due to accumulation of MEI-1, which is normally degraded via 
the Cul3-MEL-26 complex (Johnson et al., 2009). Homozygous deletion of 
the Cul3 gene in mice resulted in embryonic lethality (Singer et al., 1999). 
The embryos lacking Cul3 exhibited disorganized extraembryonic tissues 
and an increase in cyclin E protein levels. In human cultured cells, absence 
of Cul3 has been shown to inhibit cell migration (Chen et al., 2009). This is 
due to stabilization of the Cul3 substrate RhoA which controls actin 
cytoskeleton stress fiber development. Therefore, cells with reduced Cul3 
expression exhibit abnormal actin stress fibers, distorted cell morphology 
and impaired cell migration.  
 In the Cul3 E3 ligase complex, the BTB domain-containing proteins 
integrate the functions of both adaptor and substrate receptor into a single 
polypeptide. Mouse and human genomes each encode ~300 BTB domain 
proteins which possess additional protein-protein interaction domains, such 
as ankyrin repeats, Kelch repeats, MATH, and zinc finger domains. The best-
characterized BTB domain containing Cul3 substrate receptors are speckle-
type POZ domain protein (SPOP) and Keap1 (Stogios et al., 2005; Zhuang et 
al., 2009; Lo et al., 2006). The substrate binding domain of SPOP comprises 
of a MATH domain whereas Keap1 contains a Kelch repeat domain. Both 
the MATH domain and the Kelch repeat domains are involved in recruiting 
Cul3 target substrates for ubiquitination (Zhuang et al., 2009; Lo et al., 
2006).  Cul3 substrate receptor Keap1 targets the Nrf2 transcription factor 
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for ubiquitination and degradation whereas SPOP substrate receptor complex 
facilitates the ubiquitination a number of proteins, including Daxx, a 
transcriptional repressor of p53. Notably, loss-of-function mutations in 
Keap1 as well as Nrf2 mutations have been identified in different human 
cancers, particularly in the lung cancer. These mutations lead to constitutive 
activation of Nrf2 due to disruption of the Keap1-Nrf2 complex or of 
Cul3/Rbx1-Keap1 E3 ligase activity (reviewed by Hayes and McMahon, 
2009).    
 Under normal conditions, the Cul3/Rbx1-Keap1 ligase recruits Nrf2 
constitutively for polyubiquitination and consequently targets it for 
degradation to maintain low basal levels of the transcription factor (Zhang et 
al., 2004; Cullinan et al., 2004). However, Nrf2 ubiquitination is inhibited 
upon exposure of cells to electrophiles and oxidative stress due to the 
covalent modification of critical cysteine residues in Keap1. This in turn 
results in suppression of the Cul3/Rbx1-Keap1 ligase activity, an increase in 
Nrf2 stability and hence the activation of the antioxidant transcriptional 
response (Zhang et al., 2004; Cullinan et al., 2004). Expression of Nrf2-
dependent cytoprotective gene products is important to detoxify carcinogens, 
and maintain cellular redox homeostasis. Thus, Nrf2 has a dual function in 
cancer, whereby it can protect from carcinogen and ROS dependent 
tumorigenesis and promote cancer development during later stages, In view 
of these, activation of Nrf2 in healthy individuals is an important strategy for 
chemoprevention while targeted inhibition of the Nrf2 pathway may 
contribute as an effective mode in chemotherapy.  
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 With regards to the SPOP substrate receptor complex, Cul3 recruits 
the SPOP protein via its BTB domain to regulate the transcriptional 
repression activities of p53 through the degradation of Daxx (Kwon et al., 
2006). The Cul3-SPOP complex also regulates the Hedgehog pathway via 
the ubiquitination of transcription factor Cubitus interruptus (Ci)/Gli 
(reviewed in Zhang et al., 2009). 
1.7.4 CRL4 
 It is known that Cul4 is important in the regulation of the DNA 
replication process (Zhong et al., 2003). When Cul4 is being silenced, a 
dramatic level of DNA re-replication occurs. This is due to the accumulation 
of the replication-licensing factor Cdt1. CRL4 normally targets Cdt1 for 
degradation via the DCAF protein Cdt2, which functions as a substrate 
recognition subunit. As part of the pre-replication complex, Cdt1 is 
important in DNA replication. The accumulation of Cdt1 upon CRL4 
inhibition causes massive re-replication, thereby preventing the entry of cells 
into mitosis (Zhong et al., 2003).   
 In humans, Cul4 also regulates cell cycle progression by controlling 
the abundance of the p27 cell cycle inhibitor (Higa, 2006a). Thus, 
inactivation of Cul4A has been shown to stabilize the p27 protein, leading to 
a cell cycle delay or arrest in G1 (Higa, 2006a). Human Cul4A is also 
involved in the regulation of cyclin E stability. Silencing of Cul4A has been 
shown to accumulate both cyclin E and p27. However, inactivation of Cul4B 
only stabilizes the cyclin E protein but does not affect the p27 protein level 
(Higa, 2006a). Thus, it is likely that Cul4A and Cul4B are not completely 
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redundant and exert specific cellular effects.  
1.7.5 CRL7 
 Defects in Cul7 gene have been shown to be associated with the 3-
M syndrome, an autosomal recessive primordial growth disorder. This 
disease is characterized by severe pre- and post-natal growth retardation 
without mental or endocrine disorders (Huber et al., 2005; 2009). The 
restricted growth is generally associated with a spectrum of minor anomalies 
including facial dysmorphism, short broad neck, flat cheeks, winged 
scapulae, prominent fleshy heels, and hyperlordosis. Huber et al., 2005 
showed that in human cells, 3-M syndrome associated mutations in Cul7 lead 
to the inability of the cullin protein to recruit ROC1. This suggests loss of 
CRL7 dependent substrate ubiquitination is causatively involved in the 
pathogenesis of 3-M syndrome.    
 In mice, knocking out Cul7 has been shown to result in neonatal 
lethality due to respiratory distress, postnatal growth retardation, abnormal 
vascular morphogenesis and an abnormal development of the placenta. The 
only known CRL7 substrate recognition subunit is Fbxw8. Deletion of 
Fbxw8 results in a similar phenotypes compared to Cul7-deficient mice. In 
addition, Cul7 and Fbxw8 have also been reported to be involved in cell 
growth regulation and to regulate tumorigenesis through the p53 pathway in 
different cell culture systems. Inactivation of CRL7 due to mutations in Cul7 
can cause an increase in p53-mediated apoptosis activity (reviewed in 
Sarikas et al., 2008).  
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1.8 Ubiquitin-Like Protein Nedd8 
The ubiquitin-like protein, Nedd8 (Neural precursor cell-Expressed 
Developmentally Down-regulated 8) was first identified in mouse brain as 
part of a set of genes with developmentally down-regulated expression 
(Kumar et al. 1992). Human Nedd8 possesses 60% amino acid sequence 
identity and 80% similarity to ubiquitin. Like ubiquitin, Nedd8 is conjugated 
onto lysine residues in substrate proteins. The major substrates of Nedd8 are 
all members of the cullin protein family (Hori et al., 1999). The modification 
of cullins by Nedd8 is known as neddylation. Neddylation is essential in 
eukaryotic organisms with the exception of budding yeast. Similar to 
ubiquitin, Nedd8 is conjugated to a cullin lysine residue via its C-terminal 
glycine residue and this modification requires a Nedd8 specific E1 and E2 
enzyme. First, a heterodimeric Nedd8 E1 activating enzyme, which is 
composed of APPBP1 and UBA3 subunits, activates Nedd8 in an ATP 
dependent manner, thus forming a high-energy thiolester bond.  
Subsequently, the activated Nedd8 is transferred to the Nedd8 E2 
conjugating enzyme (Ubc12 / UBE2M or UBE2F) (Gong and Yeh, 1999) 
(Figure 1.3). The Nedd8 E2 enzyme is responsible for conjugating Nedd8 
onto a conserved lysine residue at the cullin C-terminus. Nedd8 conjugation 
is essential for CRLs to function in vivo. It has been shown that the E3 ligase 
complex undergoes a conformational change when Nedd8 conjugates to Cul1 
and thereby promotes the ubiquitination activity (Duda et al., 2008; Saha and 
Deshaies, 2008; Yamoah et al., 2008). In addition, neddylation has been 
revealed to promote the recruitment of the E2 ubiquitin conjugating enzyme 
to Cullin E3 ubiquitin ligases to assemble the polyubiquitin chain 
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(Kawakami et al., 2001). Thus, the neddylation activity is important for CRL 
dependent substrate ubiquitination.    
 
                     
Figure 1.3 Neddylation. Nedd8 is activated via covalent attachment to the 
Nedd8 E1 activating enzyme (E1) in an ATP-dependent manner and is 
subsequently transferred to a Nedd8 E2 conjugating enzyme (E2). Finally, 
Nedd8 is transferred from E2 to the substrate, CRL.  
 
It has been shown that conjugation of Nedd8 to the CRL complex 
prevents the binding of the cullin interacting protein CAND1 to the cullin 
complex (Duda et al., 2008). The conjugation of the Nedd8 molecule to the 
Cul5 C-terminal WHB domain has been revealed to abolish the binding site 
of CRL inhibitor CAND1 to Cul5. In addition, the Rbx1 RING domain was 
shown to be partially detached from Cul5 upon neddylation. As a 
consequence, the cullin C-terminus/Rbx1 conformation is more flexible. This 
results in more favorable catalytic geometries to mediate ubiquitin transfer 
(Duda et al., 2008; Saha and Deshaies, 2008; Yamoah et al., 2008). More 
recently, Boh et al. further confirmed this mechanism in which neddylation 
induced the conformational change in regulating CRLs activity in vivo. This 
study used deletion mutants of the cullin extreme C-terminal domain 
(ECTD) which possess a flexible conformation of the Cullin C-
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terminus/Rbx1 domain even in the absence of cullin neddylation. It was 
shown that the ECTD mutants could promote substrate ubiquitination in vivo 
even when the cellular neddylation pathway is being inhibited. The various 
studies indicate that upon neddylation, the RING domain of Rbx1 becomes 
flexible and this brings the ubiquitin charged E2 enzyme and substrate into a 
close proximity, thereby enhancing the ubiquitin transfer activity (Duda et 
al., 2008; Saha and Deshaies, 2008; Yamoah et al., 2008; Boh et al., 2011).   
 
1.9 COP9 Signalosome 
 The COP9 Signalosome (CSN) complex was initially discovered in 
Arabidopsis thaliana as a repressor of photomorphogenesis (reviewed in Wei 
and Deng 1992). Photomorphogenesis is defined as the growth and 
development of a plant which is dependent on the light sources. Plants with 
CSN mutations have been shown to exhibit a constitutive photomorphogenic 
phenotype where plants are able to grow in the dark as if they were 
cultivated in light (reviewed in Wei and Deng 1992). These plants develop 
an etiolated growth prototype in partial or complete absence of light.  
 The CSN complex is composed of eight subunits and has high 
similarity to the lid sub-complex of the 26S proteasome (Wei et al., 2008; 
Bosu and Kipreos, 2008; Petroski and Deshaies, 2005). CSN is found in 
various eukaryotic organisms, from yeast, Aspergillus, C. Elegans to 
Drosophila and mammals. It has been shown that CSN is involved in diverse 
cellular and developmental biological processes such as signal transduction, 
autophagy, T-cell development, the regulation of DNA repair, and cell cycle 
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regulation. Deletion of any different CSN subunit can cause the loss of COP9 
function, leading to embryonic lethality in Drosophila and mice (Orsborn et 
al., 2007; Dohmann et al., 2008). The lethality of CSN inactivation that 
occurred in mice is due to cell cycle defects. This has recently been 
confirmed using Cre recombinase–dependent knockout of CSN5 in mouse 
embryonic fibroblasts, which resulted in multiple cell cycle defects and cell 
death (Yoshida et al., 2010). CSN is also essential for Arabidopsis G2-phase 
progression and genomic stability (Dohmann et al., 2008). 
 There are two different domains present in different CSN subunits: 
the Proteasome/CSN/eIF3 (PCI) domain and the Mpr1-Pad1-N-terminal 
(MPN) domain (reviewed in Schwechheimer and Deng 2001). The PCI 
domain is found in the Csn1, Csn2, Csn3, Csn4, Csn7, and Csn8 subunits. It 
has been shown that PCI domains serve as structural scaffolds in the CSN as 
well as in the proteasome lid and eIF3 complexes that are related to CSN 
(Scheel and Hofmann, 2005). For the MPN domain, it can be categorized 
into two classes: normal MPN or MPN+ domains. The MPN+ domain 
comprises of a metalloprotease (Maytal-Kivity et al., 2002; Wei and Deng, 
2003). The Csn6 subunit contains only normal MPN domain whereas the 
Csn5 subunit harbors this MPN+ domain which has metalloprotease activity. 
However, the metalloprotease activity of CSN5 alone is dependent on the 
association with the other CSN subunits.  The CSN6 subunit however lacks 
metalloprotease ability. The MPN domain in the CSN6 subunit serves as an 
interaction domain instead of a metalloprotease (Zhang et al., 2012).  
 The well-known biochemical function of CSN is to catalyze the 
removal Nedd8 conjugates from CRLs. This process is termed as 
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deneddylation. Ultimately, the metalloprotease that centers in CSN5 removes 
Nedd8 conjugates from cullin proteins through its isopeptidase activity. In 
vivo, complete loss of function of CSN increases the levels of Nedd8-
conjugated CRLs. It has been revealed that CSN is important for CRLs to 
function in vivo (reviewed by Bosu and Kipreos, 2008; Wei et al., 2008). 
Thus, inactivation of CSN results in inhibition of CRL activity and 
accumulation of various CRL substrates. Therefore, it has been suggested 
that CSN serves as a positive regulator of CRL activity in vivo. However, in 
vitro, CSN-mediated deneddylation leads to inactivation of CRLs, indicating 
that CSN is a negative regulator of CRLs in vitro. The apparent opposing 
function of CSN in vitro and in vivo has been termed the CSN paradox. One 
explanation for the CSN paradox is that CSN plays a crucial role in 
protecting various cullin substrate recognition subunits from CRL mediated 
autoubiquitination. This is due to the fact that in the absence of bound 
substrate protein, CSN mediates the removal of Nedd8 from cullin, leading 
to inhibition of CRL activity. In addition, CSN associates with the 
deubiquitinase Ubp12/Usp15 and recruits this enzyme to the CRL complex, 
where Ubp12/Usp15 functions to reverse substrate-receptor 
autoubiquitination (Zhou et al., 2003; Hetfeld et al., 2005). A further 
mechanism through which CSN promotes CRL dependent substrate 
ubiquitination is by facilitating binding of CAND1 to cullin proteins. 
CAND1 interacts with all cullin isoforms only in their unneddylated form 
(see below).  
 As mentioned previously (the section 1.8 Ubiquitin-Like Protein 
Nedd8), neddylation is important for CRLs to function. On the other hand, 
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CSN mediated deneddylation is required for CRL function in vivo. Thus, this 
indicates that both neddylation and deneddylation are essential in the 
regulation of CRL activity. Based on this, a CRL activation cycle has been 
suggested (Cope and Deshaies, 2003). According to this CRL activation 
cycle, cullin neddylation is induced upon substrate binding to the CRL 
complex and subsequently leads to activation of the CRL complex. After the 
substrate becomes ubiquitinated and dissociates from the CRL complex, 
CSN removes Nedd8 from the cullin protein. The CRL activation cycle 
resumes when a new substrate binds to the CRL complex. According to this 
proposed model, CSN, therefore plays an important role in facilitating 
dynamic cycles of CRLs. Additionally, CSN can serve as a regulator in 
promoting the binding of CAND1 to the CRL complex (Cope and Deshaies, 
2003; Bosu and Kipreos, 2008). CAND1 only binds to the unneddylated 
form of cullin proteins. Furthermore, the binding of CAND1 and substrate 
recognition subunits to the cullin proteins is mutually exclusive. Hence, 
when CSN removes Nedd8 from the cullin protein, this may promote 
CAND1 binding, leading to dissociation of the substrate receptor. After 
CAND1 dissociates from CRL, a new substrate recognition subunit would 
bind to the CRL complex. As a consequence, CSN-mediated deneddylation 
may facilitate the exchange of substrate recognition subunits (Lo and 
Hannink, 2006; Schmidt et al., 2009). Alternatively, it has also been 
suggested that CSN may compete with CAND1 for binding to cullin 
proteins, thereby preventing the disassembly of the CRL complex. Finally, 
CSN has also been revealed to possess another regulatory function by 
promoting the dissociation of polyubiquitinated proteins from the CRL 
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complex (Miyauchi et al., 2008).  
 
1.10 CAND1 
CAND1 (Cullin-Associated Neddylation Dissociated 1) is a 120kDa 
cullin-binding protein. It interacts directly with both the cullin N-terminus 
and C-terminus. The CAND1 protein was initially found to be associated 
directly with TATA binding protein (TBP) (Yogosawa et al., 1996). 
Therefore, it was originally named TIP120A (TBP-Interacting Protein 
120A). The CAND1 protein was first discovered and characterized in 
Arabidopsis and humans (Feng et al., 2004, Chuang et al., 2004, Zheng et al., 
2002; Liu et al., 2002). More recent studies have shown that CAND1 
orthologs also exist in C. elegans and yeast (Bosu and Kipreos, 2008, 
Siergiejuk et al., 2009). The human CAND1 protein consists of 25 tandem 
HEAT (huntingtin, elongation factor 3, protein phosphatase 2A, TOR1) 
motifs that are known to serve as a flexible scaffold to assemble with other 
proteins (Goldenberg et al., 2004). These HEAT motifs are known to be 
involved in protein-protein interactions. Goldenberg et al. (2004) reported 
that in a crystal structure of the CAND1-Cul1-Rbx1 complex, CAND1 
employs a highly sinuous superhelical structure to wrap and fold tightly 
around the Cul1-Rbx1 complex. The CAND1 N-terminus is bound to the 
cullin C-terminus, whereas its C-terminus is bound to the cullin N-terminus. 
Binding of the CAND1 C-terminus to the Cul1 N-terminus inhibits the 
binding of the Skp1 adaptor and the substrate-recognition subunit F-box 
proteins to Cul1. On the other hand, upon binding of the CAND1 N-terminus 
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and the Cul1 C-terminus, the Cul1 C-terminal neddylation site lysine residue 
is masked by two CAND1 HEAT motifs. As a consequence, the Nedd8 
conjugation site in cullin proteins is inaccessible. Conversely, Nedd8 
conjugation to Cul1 is also able to inhibit the CAND1-Cul1 interaction. In 
addition to Cul1, CAND1 is able to associate with other cullins in human 
cells (Zheng et al., 2002; Liu et al., 2002). It binds to Cul2, Cul3 and Cul4a 
but less strongly to Cul5 in human HEK293T and HeLa cells (reviewed in 
Bosu and Kipreos, 2008).  
 Several lines of evidence have been provided that the CAND1 
protein is essential in Arabidopsis. Loss of CAND1 function in Arabidopsis 
demonstrates several distinct phenotypes, including root elongation, loss of 
apical dominance, late flowering, floral organ defects, and low fertility 
(Chuang et al., 2004; Feng et al., 2004; Cheng et al., 2004). In C. elegans. 
CAND1 mutants show developmental arrest, morphological defects of the 
vulva and tail, and reduced fecundity (Bosu et al., 2010). These findings 
suggest that CAND1 plays a critical role in regulating CRL activity in vivo. 
In further support, in a number of organisms it has been shown that absence 
of CAND1 leads to the accumulation of CRL substrates in vivo. On the other 
hand, CAND1 serves as a negative CRL regulator in vitro. It prevents CRL 
assembly and inhibits the CRL activity, as shown in previous CAND1 
biochemical studies (Zheng et al., 2002; Liu et al., 2002). There are a number 
of potential mechanisms that could account for the divergent in vivo and in 
vitro effects of CAND1. Similarly to CSN, CAND1 may play a role to 
inhibit substrate receptor autoubiquitination. For instance, it has been shown 
that CAND1 siRNA knockdown leads to decreased levels of the substrate 
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recognition protein Skp2 (Zheng et al., 2002). In addition, it has also been 
proposed that dynamic cycles of CAND1 assembly and disassembly to CRLs 
play a role in mediating the substrate receptor exchange (Lo and Hannink, 
2006; Schmidt et al., 2009). 
 A further important question relates to the mechanism through 
which CAND1 is dissociated from CRLs. One potential mechanism is that 
neddylation of cullin proteins induces the dissociation of CAND1 from the 
cullin complex (Liu et al., 2002). However, structural studies have shown 
that in the presence of bound CAND1, the neddylation site in Cul1 is 
inaccessible (Goldenberg et al., 2004). An alternative mechanism for how 
CAND1 dissociate from the CRL complex is via the binding of additional 
CRL components. For instance, it has been reported that addition of the Skp1 
adaptor and ATP to cell extracts prompts CAND1 disassembly from Cul1 
(Zheng et al., 2002). In a different study it has been demonstrated that 
addition of the Skp1-Skp2 complex together with the p27 substrate result in 
the dissociation of CAND1 from Cul1 (Bornstein et al., 2006). In conclusion, 
a number of important questions relating to the mechanism and significance 
of CAND1 binding to cullin proteins are not completely resolved.  
 
1.11 The Nedd8 Activating Enzyme 1 (NAE1) inhibitor, MLN4924 
 
 Recently, Millennium Pharmaceuticals Inc. reported the discovery 
of a drug known as MLN4924 as a promising therapeutic agent for multiple 
cancers (Soucy et al., 2009). This drug, MLN4924 is a potent and selective 
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inhibitor of the Nedd8-activating enzyme (NAE) (Soucy et al., 2009). In the 
Nedd8 conjugation pathway, NAE plays an essential role to activate the 
Nedd8 precursor and load it onto the Nedd8 E2 enzyme (Ubc12) in an ATP 
dependent manner. In the first step of Nedd8 activation, Nedd8 forms a 
covalent bond with adenosine 5′-monophosphate (AMP), thus leading to 
Nedd8-AMP formation. Nedd8 then releases the AMP molecule and forms a 
thioester bond with NAE, resulting in Nedd8-NAE formation. MLN4924 has 
been shown to form a covalent adduct with Nedd8, catalyzed by the NAE. 
The resulting Nedd8-MLN4924 resembles the structure of Nedd8-AMP. The 
Nedd8-MLN4924 adduct remains bound to the NAE active site because it 
fails to form a thioester bond with NAE in the subsequent reaction. The 
binding between the Nedd8-MLN4924 adduct and the NAE active site 
targets the Nedd8 pathway specifically, thus leading to the inhibition of the 
NEDD8 conjugation of substrates such as cullins (Brownell et al., 2010). In 
summary, this demonstrates that MLN4924 is a potent and specific inhibitor 
of NAE. 
 In MLN4924-treated cells, numerous CRL substrates such as CDT1, 
p27 and NRF2 have been shown to become stabilized (reviewed by Soucy et 
al., 2010). Soucy et al. (2009) reported that upon MLN4924 treatment, the 
steady-state levels of both the Ubc12-Nedd8 thioesters and Nedd8-Cullin 
conjugates decreased. This is consistent with MLN4924 mediated NAE 
inhibition. Importantly, it has been observed that when MLN4924 is 
administered to tumor-bearing mice, tumor growth in lung tumor xenografts 
and in HCT-116 xenografts was inhibited (Soucy et al., 2009).  Since the 
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initial discovery, many studies have shown that MLN4924 has potent 
anticancer effects in multiple cancers in vivo. 
 A major mechanism through which MLN4924 causes cancer cells to 
undergo apoptosis is through the induction of cell cycle defects. It was 
reported that treatment of MLN4924 exhibits S-phase defect in HCT-116 
cells and other human-tumor-derived cell lines (Soucy et al., 2009, Lin et al., 
2010, and Jia et al., 2011) Specifically, MLN4924 treatment leads to 
stabilization of the DNA replication licensing factor protein Cdt-1. Cdt1 is 
normally a substrate of both the CRL1SKP2 and CRL4–DDB1CDT2 E3 ligases. 
Accumulation of Cdt1 results in DNA rereplication and induction of the 
DNA damage response (Vaziri et al., 2003; Hu et al., 2004; Nishitani et al., 
2006). In addition, a number of additional mechanisms through which 
MLN4924 exerts its anticancer activity have been reported (Soucy et al., 
2009; Yang et al., 2012; Wei et al., 2012). 
 MLN4924 is currently being evaluated in a number of clinical trials 
and has shown encouraging results in patients with Acute Myeloid Leukemia 
(Sword et al., 2010). The phase 1 clinical trial of MLN4924 that has been 
performed in patients with relapsed and/or refractory multiple myeloma or 
lymphoma, including Hodgkin lymphoma and non-Hodgkin lymphoma, 
demonstrated a partial response or stable disease (Sword et al., 2010). This 
and other clinical trials suggest that targeting Cullin E3 ubiquitin is a 
promising strategy for anti-cancer therapy (reviewed by Soucy et al., 2010). 
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Figure 1.4 The chemical structure of MLN4924 ((1S,2S,4R)-4-{4-[(1S)-2,3-
dihydro1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl} 





























2.0  Aims of The Study  
In this study, we aim to address the global regulatory mechanisms that 
govern CRL activity. 
I) Regulation of CRLs by CSN in vivo!. The aim of the study is to 
characterize the regulation of CRLs by CSN. 
II) Mechanism of Cullin3 E3 ubiquitin ligase dimerization. The aim of the 
study is to resolve the two different proposed CRL3 dimerization models. 
III) Identification and characterization of SCFF-box protein substrates. The aim 












3.0 Materials and Methods 
 
 
3.1 Plasmid Constructs 
 
  To generate N-terminally 2X Flag-tagged expression constructs for 
Nedd8, CSN5, SPOP, Keap1, Gkap1, ACBD5 and CIF (Flag-Nedd8, Flag-
CSN, Flag-SPOP, Flag Keap1, Flag-Gkap1, Flag-ACBD5 and Flag-CIF), 
modified pcDNA3.1/Zeocin plasmid was used. The Nedd8 (NM_006156.2), 
Gkap1 (NM_025211.3) and ACBD5 (NM_145698.3) were cloned from 
HEK293 cDNA and both SPOP (NM_001007226.1) and CSN5 
(NM_006837.2) were amplified from MGC I.M.A.G.E. clones, whereas the 
human Keap1 (Image 3163902) cDNA I.M.A.G.E. clone was purchased 
from the Geneservice Ltd. Company. For the Flag-CIF plasmid, B. 
pseudomallei Cif was PCR amplified using the following PCR primers: 
5′AGGGTACCATGTTGGAGCACGGCGTCAT (forward primer for full-
length Cif (amino acids 1–328) including a KpnI site), and 
5′ATTCTAGATTAGCCAAGGCCGGCGACGTA (reverse primer including 
an XbaI site). The PCR products were resolved by agarose gel 
electrophoresis to ensure that the products were of the correct size. The 
respective gel-purified PCR product was digested with KpnI (Roche) and 
XbaI (Fermentas) restriction enzymes. The Tanggo buffer (Fermentas) was 
used for digestion. The PCR products were then inserted into modified 
pcDNA3.1, which includes an N-terminal 2× FLAG tag sequence.  
For the Cul1, Cul2, Cul3, β-TrCP and SLBP with C-terminally V5-
tagged expression constructs (Cul1-V5, Cul2-V5, Cul3-V5, β-TrCP-V5 and 
SLBP-V5), the murine Cul1, human Cul2 and Cul3 cDNA I.M.A.G.E. clones 
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were also purchased from Geneservice Ltd. (Image identifiers 2812400, 
4104375, and 6168545 respectively), the respective cDNA was PCR 
amplified, as well as Kozak consensus sequence and start codon in the 5’ end 
primer whereas the 3’ end primer contains the V5 epitope tag followed by 
the stop codon. Each amplified PCR product was then inserted into pcDNA3 
via these two sites, Kpn1 (Roche) and SacII (Fermentas). For the Cdc34-HA 
and Tulp1-Flag plasmids, the human Cdc34 (NM_004359.1) and the human 
Tulp1 (NM_003322.3) were cloned from HEK293 cDNA and were inserted 
into pcDNA3 including C-terminal HA-tag and C-terminal Flag-tag, 
respectively.  
To generate C-terminally V5-tagged expression constructs for the 
N-terminal deletion constructs of Cul3 (amino acids 392-768) and C-terminal 
deletion construct of Cul3 (amino acids 1-427) (Cul3(392-768)-V5 and 
Cul3(1-427)-V5), the respective cDNA was PCR amplified and inserted into 
the Kpn1 and SacII sites of modified pcDNA3. The Cul2(NT)- Cul3(CT)-V5 
plasmid was generated by fusing the N-terminus of Cul2 (amino acid 1-394) 
to the C-terminus of Cul3 (amino acid 392-768) which also carrying a C-
terminal V5-tag in a modified pcDNA3 plasmid.  
QIAquick Gel Extrction Kit (QIAGEN) was used to perform DNA 
gel extraction and purification. After gel electrophoresis, the DNA fragment 
of interest was excised and weighed. The gel slice was dissolved in the QG 
buffer (3 volumes of buffer QG to 1 volume of gel slice). 150 All these DNA 
plasmids were extracted by using Axygen mini plasmid preparation kit and 





 The C111S ubc12 (dnUbc12), D151N CSN5, K720R Cul1, K712R 
Cul3, L52AE55A Cul3 (Cul3LE) and D53A/F54A/E55A Cul3 (Cul3SFE) 
mutants were carried out using the Strategene site-directed mutagenesis kit. 
The T-Rex system (Invitrogen) was used to generate cell lines with 
tetracycline-induclible expression of dnUbc12-HA. 
 
 
3.3 Cell culture 
HEK293T, HCT116, and Hela cells (ATCC) were cultured on T25 
flask (Iwaki, Japan) in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 
penicillin-streptomycin, and L-glutamine at 37 °C and 5% CO2 incubator 
(Thermo Scientific, IGO 150 cell life). In addition, nystatin, an antifungal 
drug, was added to the cultured cells at final concentration of 0.2% (v/v). 
The cells were subcultured when 80% confluence. Subsequently, cells were 
seeded using the ratio 1:8 on 12-well (Greiner Bio-One, Germany) or 60 mm 
(Nunc, Denmark) or 100 mm (Greiner Bio-One, Germany) plates according 
to need one day prior to experiment.  
 
3.4 Plasmid DNA transfection 
Plasmid DNA transfections were performed with GeneJuice® 
Transfection Reagent (Novagen) according to the manufacturer’s guide using 
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2.7 μL of GeneJuice reagent per 1 μg of DNA two days prior to cell 
harvesting. Briefly, the required amount of GeneJuice reagent was added to 
100 μL of serum free medium (Invitrogen) and incubated at room 
temperature for five minutes. Subsequently, the required amount of plasmid 
DNA was added to the mixture and the GeneJuice reagent/DNA mixture was 
incubated at room temperature for 15 minutes. The mixture was finally 
added to the 12-well or 60 mm or 100 mm plates drop-wise. The amount of 
plasmid DNA was equalised in all transfection by adding empty vector. 
Proteasome inhibitor MG132, protein synthesis inhibitor cycloheximide, or 
cullin ligase inhibitor MLN4924 was added to the cell medium six hours 
prior to harvesting. In addition, MLN4924 was also added to the cell medium 
24 hours prior to harvesting. 
 
3.5 siRNA-mediated gene knockdown 
RNAi Max Lipofectamine (Invitrogen, Carlsbad, CA) was used as 
the transfection agent according to the manufacturer’s instructions with the 
following annealed Silencer predesigned siRNA duplexes (Ambion, Austin, 
TX) at a final concentration of 25 nM: CAND1: siRNA ID 140584; CSN5: 
siRNA ID 214069; negative controls: Silencer negative control siRNA #2 or 
Mdm2 siRNA 122297. Briefly, 20 μM of the siRNA was added to 100 μL of 
serum free medium and incubated at room temperature for five minutes. At 
the same time, 2.5 μL of Lipofectamine® was added to 100 μL of serum free 
medium. The two mixtures were mixed and then incubated at room 





The cells were washed with ice-cold phosphate-buffered saline and 
lysed in Triton X-100-containing lysis buffer. Lysates were precleared by 
centrifugation before use for Western blotting. Equal amounts of protein 
(lysates: 50μg; Immunoprecipitation: 1200μg) were loaded for Western blot 
analysis. The following antibodies were used: rabbit polyclonal anti-Cul1 
(Neomarkers), Cul2 (Zymed Laboratories), Cul3 (Zymed Laboratories), 
mouse monoclonal anti-V5 (AbD Serotec), rat monoclonal anti-HA (Roche), 
mouse monoclonal anti-Flag M2 (Sigma-Aldrich), mouse monoclonal anti-
SLBP (Novus Biologicals), mouse anti-p27 (Zymed Laboratories), 
monoclonal anti-p21 (F-5) (Santa Cruz Biotechnology), monoclonal anti-
GAPDH (US Biological) and monoclonal anti-α-tubulin (Molecular Probes).  
 For the blot using Oddyssey Infrared Imaging System (LI-COR 
Biosciences), sample amounts were determined and quantitated via IRDye 
800CW in the 800nm channel of detection. 
 
3.7 Immunoprecipitation 
V5 antibody (2.5 μg) coupled to 20 μl of protein G-Sepharose 
(Amersham Biosciences), or 20 μl of Flag-agarose (Sigma) was used for 
immunoprecipitations. 500 μl of precleared lysate from HEK293T cells 
transfected in 60mm tissue culrure plates was added. The samples were 
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tumbled for 2 hours at 4°C. Subsequently, the beads were washed four times 
in 1ml of NP40 cold lysis buffer (containing 50mM NaCl, 0.5% NP-40, 5% 
glycerol, 0.5mM EDTA, 50 mM Tris (pH 7.5), 1mM dithiothreitol) and once 
in buffer containing 50mM Tris (pH7.5). The immunoprecipitated proteins 
were then denatured in SDS sample buffer and subjected to SDS-PAGE and 
Western blotting.  
 
3.8 ATP measurement 
ATP measurement in intact cells using transfected firefly luciferase: 
Cells in 12- well plates were transfected with 0.2 μg of a firefly luciferase-
pcDNA3 plasmid (under control of the CMV promoter) for 24 hours. 
Subsequently, cells were trypsinized and resuspended in Krebs buffer 
(containing 118mM NaCl, 4.8mM KCl, 1.2mM KH2PO4,, 1.2mM MgSO4, 
1mM CaCl2,, 25mM Tris(pH7.5)). Intracellular ATP concentrations were 
determined by measuring the luminescence of aliquots of cells treated with 
myxothiazole and iodoacetate for various periods of time. 20 μl of the cells 
were then mixed with 100 μl of luciferase substrate, D-luciferin (Sigma) and 
used for ATP measurement. 
ATP measurement in cell extracts: Cells in 12-well plates were 
treated with myxothiazole and iodoacetate for different periods of time. 6% 
perchloric acid was used to extract the ATP from cells and the extract was 
spun for 1 minute. The supernatant was collected and neutralized with 
1.6K2CO3 containing 0.43M triethanolamine buffer. The supernatant was 
spun for 1 minute and used for ATP measurement by using the ENLITEN 
ATP assay system (Promega).  
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3.9 Cell synchronization  
Hek293T cells synchronized at G1/S phase by blocking with thymidine 
(2.5 mM) for 16 hours. The cells were washed and released in complete 
medium. The cells were then collected at 0, 2, 4, 8, 10 hours after release 
from G1/S phase.  
 
3.10 Proximity ligation assay 
Cells were grown on coverslips and co-transfected with Cul3-V5 and Cul3-
Flag. After 12 hours, the transfection medium was changed to serum-free 
medium. Cells were incubated another 12 hours and subsequently washed 
twice in ice-cold PBS and fixed for 10 minutes with 4% paraformaldehyde in 
PBS at room temperature. TritonX-100 (0.1%) was used to permeabilize the 
fixed cells followed by incubation with Rhodamine-phalloidin (Sigma) for 
1.5–2 h to stain actin filaments.!Cells were then blocked in 1× blocking stock 
(Olink Bioscience, Uppsala, Sweden) for 30 minutes at 37°C. Mouse anti-
MYC (1:1000; Sigma-Aldrich) and rabbit anti-FLAG (1:200; Sigma-
Aldrich) primary antibodies were diluted in 1× antibody diluent stock (Olink 
Bioscience) and co-incubated overnight at 4°C. Subsequently, anti-mouse 
PLA MINUS and anti-rabbit PLA PLUS secondary probes (Olink 
Bioscience) were diluted 1:5 in 1× antibody diluent stock and co-incubated 
for 45 minutes at 37°C. This was then followed by the 1× hybridization stock 
(Olink Bioscience) incubation for 15 minutes at 37°C. Subsequently, T4 
DNA ligase (1:40) was added into 1× ligation stock (Olink Bioscience), and 
were incubated 15 minutes at 37°C. This was then followed by the 1× 
amplification stock (Olink Bioscience) incubation for 60 minutes at 37°C. 
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Finally, Texas red–labeled oligonucleotide detection probes (Olink 
Bioscience) were incubated as 1× detection stock and incubated for 60 
minutes at 37°C. Coverslips were mounted on slides using Vectashield 



























Chapter One:  
Characterization of the role of the COP9 
signalosome in regulating cullin E3 














The COP9 signalosome (CSN) is an evolutionary conserved 
multisubunit complex that plays an important role in the ubiquitin-
proteasome pathway. It contains eight small subunits, named CSN1 to CSN8 
according to their size.  CSN was first discovered in plants and has been 
shown to serve as a negative regulator of photomorphogenesis. In addition, it 
is critical for adult fertility in C. elegans. Loss of function of CSN has been 
reported to lead to lethality in Drosophila and mice. This is due to cell cycle 
defects resulting from CSN disruption. In support, Yoshida et al., 2010 have 
recently shown that in mouse embryonic fibroblasts, Cre recombinase-
dependent CSN5 knockout causes multiple cell cycle defects and leads to 
cell death (Yoshida et al., 2010). This highlights that CSN has an essential 
function not only in plants but also in metazoans.    
 The main biochemical function of CSN is to remove the ubiquitin-
like protein Nedd8 from cullin proteins (Lyapina et al., 2001; Cope et al., 
2002). The mammalian cullin protein family consists of seven members 
(Cul1, Cul2, Cul3, Cul4a, Cul4b, Cul5 and Cul7). Each of them serves as a 
scaffold protein for the assembly of the RING domain protein Rbx1 and 
different adaptor proteins to form a cullin RING E3 ubiquitin ligase (CRL) 
complex. All cullin proteins bind Rbx1 via their C-terminus and specific 
adaptor proteins via their N-terminus. Rbx1 is responsible for recruiting the 
ubiquitin-charged E2 conjugating enzyme whereas the adaptor protein is 
important for binding of the cullin specific substrate recognition subunit 
proteins. 
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The CRL complex functions to mediate the ubiquitination of its 
substrates. The CRL complex is first activated via the Nedd8 modification 
(neddylation) on the cullin protein and this is a prerequisite for substrate 
ubiquitination. The Nedd8 polypeptide is conjugated via its C-terminal 
glycine residue to a specific, highly conserved lysine residue in the cullin 
protein. This modification involves a heterodimeric Nedd8 activating E1 
enzyme, which requires an ATP hydrolysis reaction and a Nedd8 E2 
conjugating enzyme. Neddylation is important for the CRL activation 
because it induces a conformational change in the cullin C-terminus and 
thereby confers flexibility to the Rbx1 RING domain. Thus, this leads to 
promotion of ubiquitin transfer from the ubiquitin-charged E2 enzyme onto 
the substrate (Duda et al., 2008; Saha and Deshaies, 2008; Yamoah et al., 
2008).  
It has been shown that CSN mediated cullin deneddylation inhibits 
the CRL function in vitro. Thus, this indicates that CSN serves as a negative 
regulator of the CRL complex in vitro. However, in vivo, CSN has been 
revealed to serve as a positive regulator of the CRL complex. Loss-of-
function of CSN has been reported to result in the accumulation of CRL 
substrates as a result of the inhibition of the CRL activity in vivo. The finding 
that CSN-mediated deneddylation has a positive role in regulating the CRL 
activity suggests that in vivo, both neddylation and deneddylation are 
important for CRL complex function. To account for this, it has been 
suggested that CRL complexes undergo dynamic neddylation and 
deneddylation cycles in vivo. Based on this, a CRL activation cycle has been 
proposed (Figure 4A) (Cope and Deshaies, 2003). According to this 
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proposed CRL activation cycle, the binding of a substrate to the CRL 
complex induces the neddylation of the cullin protein. This therefore leads to 
activation of the CRL complex. The substrate is subsequently ubiquitinated, 
followed by its dissociation from the activated CRL. The CSN complex then 
removes Nedd8 from the cullin protein to inactivate the CRL complex. This 
CRL activation cycle resumes when a new substrate is bound to the CRL. In 
my project, I tried to determine the dynamics of the neddylation and 
deneddylation cycle in intact cells. In addition, I investigated whether CSN-
mediated deneddylation is coupled to substrate ubiquitination, as predicted 
by the proposed CRL activation cycle.  
                   
Figure 4A: Previously proposed CRL neddylation/deneddylation 
activation cycle (Cope and Deshaies, 2003). First, a substrate binds to the 
assembled CRL complex (I) and the Nedd8 molecule is subsequently 
conjugated to the cullin protein (II), leading to activation of the CRL. This 
then leads to substrate ubiquitination and subsequent dissociation of the 
polyubiquitinated substrate (III). Finally, CSN deneddylates and inactivates 
the CRL complex (IV), followed by the possible exchange of the substrate 
receptor and adaptor protein (V). The cycle can be repeated when a new 
substrate binds to the CRL complex.  
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A more complex model including the cullin-binding protein 
CAND1 has also been proposed (Figure 4B). Based on this model, the CRL 
complex is switching between CAND1 and CSN cycles (Schmidt et al., 
2009). In the CSN cycle, substrate binding induces cullin neddylation, 
therefore leading to substrate ubiquitination. Upon substrate ubiquitination, 
CSN mediates cullin deneddylation. The CRL complex thereby exists in a 
state where no substrate and Nedd8 are bound. This allows the CRL complex 
to enter into the CAND1 cycle. In the CAND1 cycle, the CAND1 protein 
binds to the CRL complex, thereby releasing the substrate receptor protein 
from the cullin protein. Subsequently, to ubiquitinate a new substrate, 
CAND1 has to be removed from the CRL complex to replace it with a new 
substrate receptor protein and enter into the CSN cycle again. Therefore, 
based on this, it has been proposed that the CAND1-cullin binding upon 
CSN-mediated deneddylation might play an important role in promoting the 
substrate receptor exchange (Lo and Hannink, 2006; Schmidt et al., 2009). 
In the current study, I investigated the validity of the proposed 
model as well as of alternative models to gain further insight into the role of 
CSN in CRL regulation. 
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Figure 4B: Model for switching of CRL between the CAND1 and CSN 
cycles. First, a substrate binds to the activate form of the CRL complex (I). 
After substrate ubiquitination, CSN then deneddylates and inactivates the 
CRL complex (II). In the absence of bound substrate, the inactive form of 
the CRL complex recruits CAND1, resulting in the dissociation of the 
substrate receptor subunit (CAND1 cycle) (III). The cycle resume when a 
new substrate receptor subunit binds to the CRL complex and CAND1 is 













4.1.1 Overexpression of dominant negative form of Ubc12 (dnUbc12) 
decreases Cul1 neddylation 
To study the dynamics of cullin neddylation, it is important to be 
able to inhibit the Nedd8 conjugation of cullin proteins. It is known that 
Ubc12 is involved in recruiting Nedd8 from the Nedd8 E1 activating enzyme 
and transferring the Nedd8 molecule onto the substrate (Kawakami et al., 
2001; Duda et al., 2008). The C111S mutant of Ubc12 (dnUbc12) has 
previously been reported to inhibit cellular neddylation (Wada et al., 2000, 
Chew et al., 2007). This mutant binds covalently to Nedd8 but is unable to 
transfer Nedd8 onto the substrate lysine. To test this, we first verified that 
dnUbc12 could inhibit cullin neddylation. In the experiment in Figure 4.1, 
we used a HEK293 cell line that is stably transfected with dnUbc12 under 
control of a tetracycline-inducible promoter (Chew et al., 2007). A C-
terminal HA-tag was included to facilitate dnUbc12 detection. dnUbc12 was 
induced with 1 µg/ml tetracycline for the indicated times (0, 2, 4, 7, 24 
hours) and Cul1 neddylation was measured using western blotting. As shown 
in the last panel of Figure 4.1, the dnUbc12 expression was increased over 
the time upon addition of tetracycline. Based on the first panel of Figure 4.1, 
the upper bands corresponding to the neddylated form of Cul1 decreased 
gradually over the time of tetracycline induction whereas the bottom bands 
corresponding to the unneddylated form of Cul1 remained the same. This 
indicates that overexpression of dnUbc12 could decrease Cul1 neddylation. 
CRL substrates, p27 and Nrf2, were also shown to accumulate upon 
tetracycline induction. This suggests that by overexpressing dnUbc12 in the 
cells, CRLs become inactive. Consequently, the CRL substrates p27 and 
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Nrf2 could not be ubiquitinated and degraded.  
                                
Figure 4.1 dnUbc12 cells were transfected with Cul1-V5 and treated with 1 
μg/ml tetracycline in a 12-well cell culture plate for the indicated times. Cell 
lysates were collected at different time points and analyzed by Western 




4.1.2 Overexpression of dominant negative Ubc12 (dnUbc12) abolishes 
Cul5 neddylation   
          
Next, we continued to investigate the mechanism through which 
dnUbc12 inhibits cellular neddylation. Here, we hypothesized that dnUbc12 
may inhibit cullin neddylation by sequestering cellular Nedd8 or 
alternatively by preventing binding of endogenous Ubc12 to the Nedd8 E1 
enzyme or to the Cullin substrate. It is known that the neddylation of Cul1, 
Cul2, Cul3, Cul4a and Cul4b is mediated via the Ubc12 enzyme. In contrast, 
Cul5 neddylation is catalyzed by the Ube2F enzyme and not the Ubc12 
enzyme (Huang et al., 2009). Thus, to determine whether the dnUbc12 
mutant inhibits cullin neddylation via sequestering cellular Nedd8 or by 
preventing binding of endogenous Ubc12 to the Nedd8 E1 enzyme, we first 
transfected Cul5-V5 into a tetracycline-inducible dnUbc12-HA. 
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Subsequently, the cells were treated with 1 µg/ml tetracycline for the last 24 
hours and Cul5 neddylation was investigated using western blotting. As 
shown in Figure 4.2, the Cul5 neddylation band disappeared upon 
tetracycline induction. Thus, overexpressing the dominant negative form of 
Ubc12 in the cell abolished Cul5 neddylation even though Cul5 neddylation 
is not mediated via Ubc12. Because dnUbc12 is unlikely to compete with 
Ube2F for binding to the Nedd8 E1 enzyme or Cul5, the result suggests that 
dnUbc12 is likely to interfere with cullin neddylation by sequestering Nedd8. 
  
Figure 4.2 Cells with stable expression of dnUbc12-HA under control of a 
tetracycline-inducible promoter were transfected with Cul5-V5 and induced 
with 1 µg/ml tetracycline for the last 24 hour as indicated. Cell lysates were 
analyzed by Western blotting with V5 and HA antibodies. The upper band in 




4.1.3 Effect of dnUbc12 induction on cellular Nedd8 protein 
concentrations    
 
 Because dnUbc12 inhibits cullin neddylation by sequestering the 
Nedd8 protein, we next tried to determine the effect of dnUbc12 induction on 
the abundance of cellular Nedd8. In this experiment, an untagged Nedd8 was 
transfected into a dnUbc12-HA cell line under control of a tetracycline-
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inducible promoter. Subsequently, the cells were treated with 1 µg/ml 
tetracycline for 4, 8, 15, and 28 hours and the cellular Nedd8 protein was 
investigated using western blotting. Based on the first panel in Figure 4.3, 
endogenous Nedd8 was only detectable at time zero and became 
undetectable in the untransfected samples (see lane 1, 4, 6, 8) upon dnUbc12 
induction. This suggests that Nedd8 was depleted. A marked increase was 
observed in transfected or endogenous (untransfected) Nedd8 bound to 
dnUbc12 upon addition of tetracycline (see lane 3 to lane 8). In fact, the 
endogenous (untransfected) Nedd8 (see lane 4, 6, 8) that bound to dnUbc12 
was more abundant compared to monomeric Nedd8. This suggests that 
dnUbc12 depletes the cellular Nedd8 protein and limits the cellular Nedd8 
concentration. As expected, we also observed a marked reduction in cullin 
neddylation upon dnUbc12 induction. This effect was reversed upon Nedd8 
overexpression, further suggesting that dnUbc12 depletes cellular Nedd8. 
Finally, consistent with the function of dnUbc12 by sequestering Nedd8, we 
found that overexpressing Nedd8 reversed CRL inhibition. Thus, based on 
the p27 and Nrf2 blots, when Nedd8 was transfected into cells to increase the 
cellular Nedd8 concentration, the CRL substrates p27 and Nrf2 were no 
longer stabilized. Taken altogether, these results suggest that dnUbc12 is 
able to limit the cellular Nedd8 concentration by sequestering the Nedd8 
protein. 
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Figure 4.3 dnUbc12-HA cells were transfected with Nedd8 or empty vector 
as indicated and were treated with 1 μg/ml tetracycline for 4 h, 8 h, 15 h and 





4.1.4 In vivo role of CSN  
It is known that neddylation is playing an important role for cullin to 
function. However, cullin neddylation is not permanent. Nedd8 can be 
removed from cullin proteins by the COP9 signalosome (CSN). CSN has 
been shown to inhibit the function of CRL in vitro. Thus, this suggests that 
CSN acts as a CRL negative regulator in vitro.  However, CSN has been 
reported to serve as a CRL positive regulator in vivo. Knockdown or 
knockout in different model organism has been shown to reduce cullin ligase 
activity. This means that CSN is required for the CRL activity in vivo. To 





Hypothesis 1: CSN promotes CRL activity by mediating cycles of   
neddylation and deneddylation. 
4.1.4.1 Deneddylation rate of Cul1 and Cul2 in HEK293 cells. 
Both neddylation and deneddylation are required for the substrate 
ubiquitation activity in vivo. Thus, it has been proposed that the cycle of 
neddylation and denddylation in vivo is very fast and rapid (Cope and 
Deshaies, 2003; Bosu and Kipreos, 2008; Wei et al., 2008). To verify this, 
we first treated the cells with the specific inhibitor of cullin neddylation 
MLN4924 before lysing the cells. The cells were lysed at the indicated time 
points and cell lysates were analyzed by Western blotting with Cul1 and 
Cul2 antibodies. As shown in Figure 4.4, the deneddylation rates of 
endogenous Cul1 and Cul2 in HCT116 cells were relatively fast. After 
addition of the MLN4924 inhibitor, the denddylation rates for Cul1 and Cul2 
showed a marked decrease at 5 minutes and at 15 minutes, respectively. 
Thus, this result confirms that the cullin deneddylation rate in HCT116 cells 
is very fast and consequently that the cycle of neddylation and deneddylation 
is dynamic. 
                                    
Figure 4.4: HCT116 cells were grown in 12-well plates and 3 μM MLN4924 
was added at time zero. Cells were lysed at the indicated time points and cell 





4.1.4.2 Cul1 deneddylation is constitutive and not dependent on and 
coupled to substrate ubiquitination. 
Based on the CRL activation cycle that has been proposed, cullin 
neddylation occurs in the presence of a bound substrate. Subsequently, cullin 
deneddylation occurs after the substrate has been polyubiquitinated and 
dissociated from cullin (Cope and Deshaies, 2003; Bosu and Kipreos, 2008). 
Thus, according to this, we hypothesized that cullin deneddylation is coupled 
to substrate ubiquitination. Because the cycle of neddylation and 
denddylation is very fast and dynamic, it was thus necessary to inhibit 
substrate ubiquitnation acutely in determining this hypothesis. We first tried 
to use the only commercially available ubiquitination inhibitor, PYR-41, to 
test this hypothesis. It however proved to be inefficient in stabilizing known 
ubiquitin proteasome substrates such as p27 (data not shown). As an 
alternative approach, we cotreated cells with 2.5 mM of the glycolysis 
inhibitor iodoacetate and 1 μM of the mitochondrial electron transport chain 
inhibitor myxothiazol to rapidly deplete the cellular ATP required for 
ubiquitination at the step of ubiquitin activation by the E1 enzyme. As shown 
in Figure 4.5, the measured cellular ATP concentrations reached virtually 
zero after ten minutes. This suggests that the two inhibitors iodoacetate and 
myxothiazol can rapidly deplete the cellular ATP.          
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Figure 4.5: Cells were co-treated with 1 μM myxothiazol and 2.5 mM 
iodoacetate to rapidly deplete cellular ATP concentrations. ATP 
concentrations were measured as described in Materials and Methods. 
Next, we performed experiments in which we compared the Cul1 
deneddylation rate in the presence of the specific neddylation inhibitor 
MLN4924 with that upon rapid ATP depletion. The latter treatment results in 
the inihibition of both neddylation and ubiquitination (both are ATP 
dependent processes). We conducted these experiments in HEK293, 
HCT116 and HeLa cell lines. As shown in Figure 4.6, there was no 
significant difference in the Cul1 deneddylation rate between the MLN4924 
treatment and the ATP depletion condition. This suggests that deneddylation 
of cullins is not dependent on ongoing substrate ubiquitination. 
Subsequently, we tried to preincubate the cells with iodoacetate and 
myxothiazol for 5 minutes prior to the addition of MLN4924 to ensure more 
ATP depletion during the deneddylation chase period. However, as shown in 
Figure 4.7, the rate of Cul1 deneddylation in the ATP depleted condition did 
not decrease further. This further suggests that deneddylation is independent 
of ongoing substrate ubiquitination. 
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FIGURE 4.6: HEK293, HCT116 and HeLa cells were treated with 
myxothiazol (1 μM) and iodoacetate (2.5 mM) prior to addition of MLN4924 
at time zero. The cells were lysed at the indicated time points and cell lysates 
analyzed by Western blotting with Cul1 antibody.  
 
 
FIGURE 4.7: HEK293, HCT116 and HeLa cells were pre-treated for 5 mins 
with myxothiazol (1 μM) and iodoacetate (2.5 mM) prior to addition of 
MLN4924 at time zero. The cells were lysed at the indicated time points and 
cell lysates analyzed by Western blotting with Cul1 antibody.  
 
Based on previous data (Figure 4.7), the deneddylation rate of Cul1 
differed slightly between the different cell lines. The different rates may be 
due to the different CSN expression level in each cell line. Thus, to 
determine this, we measured the CSN expression level in each cell using 
Western blotting. However, as shown in the Figure 4.8, the abundance of the 
CSN2 and CSN5 proteins is similar in the three cell types. Thus, this 
suggests that the difference in the Cul1 deneddylation rate in these three cell 
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lines is likely unrelated to the CSN expression level. 
                        
FIGURE 4.8: HEK293, HCT116 and HeLa cells plated into a 12-well plate. 
The cells were lysed after 2 days and lysates analyzed by Western blotting 
with the indicated antibodies.  
 
To further determine whether the substrate ubiquitination is 
followed by Cul1 deneddylation, we used the proteasome inhibitor MG-132 
to inhibit the degradation of polyubiquitinated proteins. In this experiment, 
the Cul1 deneddylation rates were measured upon addition of MLN4924 in 
the presence or absence of MG-132. We pretreated the cells with MG-132 
for 20 minutes prior to the addition of MLN4924. Cells were then lysed at 
the indicated time-points and lysates were analyzed by Western blotting with 
the Cul1 antibody. As shown in Figure 4.9, the Cul1 deneddylation rates 
showed no difference when the degradation of polyubiquitinated substrate 
was inhibited. This result further confirms that Cullin deneddylation is not 
coupled to substrate ubiquitination.  
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FIGURE 4.9: 3 μM MLN4924 was added at time zero to HEK293 cells that 
were pretreated with 20 μM MG-132 for 20 minutes. Cells were lysed at the 
indicated time-points and cell lysates were analyzed by Western blotting 





4.1.4.3 CAND1 siRNA does not affect on the Cul1 deneddylation rate 
   
It has been suggested that the CAND1 protein promotes cullin 
deneddylation (Min et al., 2005; Chew et al., 2007), we also determined the 
effect of small interfering RNA (siRNA)-mediated silencing of CAND1 on 
the deneddylation rate in HEK293 cells. As shown in Figure 4.10, CAND1 
silencing resulted in an increased basal Cul1 neddylation level, indicating 
that the knockdown of the CAND1 protein was functional. However, 
silencing of CAND1 was without effect on the rate of Cul1 deneddylation, 
even when the initial deneddylation rate was monitored during the first 
minutes after addition of MLN4924 (Figure 4.11). 
 
FIGURE 4.10: Cells were transfected with negative control or CAND1 
siRNA for 3 days. Cells were lysed at the indicated time-points and cell 
lysates were analyzed by Western blotting with the indicated antibodies. NS, 




FIGURE 4.11: Cells were transfected with negative control or CAND1 
siRNA for 3 days. Cells were lysed at the indicated time-points and cell 
lysates were analyzed by Western blotting with the indicated antibodies. NS, 





4.1.4.4 Overexpression of Cdc34 does not affect the Cul1 deneddylation 
rate 
Because previous approaches used were to inhibit cullin 
ubiquitination, we next changed the method to promote cullin ubiquitination 
by overexpressing the ubiquitin E2-conjugating enzyme, cdc34. In this 
experiment, the cells were transfected with cdc34-HA in the treatment of 
MLN4924. As expected, overexpression of cdc34 resulted a decreased 
expression level of the Cul1 substrate p27. However, this does not cause any 
changes in the Cul1 deneddylation rate (Figure 4.12). Taken together, these 
results suggest that cullin deneddylation is not coupled to the substrate 
ubiquitination.   
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FIGURE 4.12: HEK293 cells were transfected with empty vector or cdc34-
HA expression plasmid, as indicated. Cells were lysed at the indicated time-




Hypothesis 2: CSN-mediated cullin deneddylation facilitates substrate 
receptor exchange 
 
4.1.4.5 Role of CSN in promoting the exchange of the Cullin3 substrate       
receptor SPOP 
Based on a model suggested by Schmidt et al., 2009, in which the 
CRL complex is switching between CAND1 and CSN cycles, it has been 
proposed that CSN-mediated cullin deneddylation is essential for the 
substrate receptor exchange. According to this model, cullin neddylation is 
induced in the CSN cycle when a substrate binds to CRL. Subsequently, 
substrate-induced neddylation leads to substrate ubiquitination. After the 
substrate is being ubiquitinated and dissociated from the CRL complex, CSN 
removes Nedd8 from the cullin protein. In the absence of substrate and 
Nedd8 unbound condition, the CRL together with substrate receptor bound 
complex prompts to enter CAND1 cycle in which the CRL complex would 
release the substrate receptor from cullin upon recruiting the CAND1 
protein. In order to ubiquitinate a new substrate, CAND1 has to be removed 
from the cullin protein to recruit a new substrate receptor again. Thus, it has 
been suggested that the CAND1-cullin binding upon CSN-mediated 
deneddylation would promote the CRL complex to undergo continuous and 
rapid switching between CAND1 and substrate receptor subunits. To resolve 
this hypothesis, the dynamic rates of assembly and disassembly of the 
substrate receptor with cullins were determined in the absence of CSN or 
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CAND1. First, we introduced new substrate-receptor proteins into cells by 
transfecting the recombinant substrate-receptor proteins (using the 
ProteoTuner System, Clontech) and measured the rates of binding of the 
substrate receptor and cullin proteins. However, the binding of the 
transfected substrate-receptor proteins to cullins was shown insignificant in 
cells. This suggests that the method of protein transfection was ineffective to 
introduce the recombinant substrate receptor proteins into cells. Second, we 
included positively charged protein transduction domains into the 
recombinant proteins to facilitate cellular uptake. However, this approach 
also proved to be inefficient. Next, we utilized another approach to introduce 
the new substrate receptor protein. We tried to induce a substrate-receptor 
protein using a tetracycline-inducible expression system in cells (Figure 
4.13). An expression plasmid for the Cul3 substrate receptor SPOP under 
control of a tetracycline-inducible promoter was generated and transfected 
together with Cul3-V5 into HEK293 cells with CSN5 siRNA knockdown or 
control cells. 1 µg/ml of tetracycline was added at the time zero to induce the 
expression of the SPOP substrate receptor. Subsequently, cells were lysed at 
the indicated time points and the binding of the SPOP substrate receptor to 
Cul3 was measured using co-immunoprecipitation assays. As shown in the 
input in Figure 4.13, the SPOP protein was induced in a time dependent 
manner after addition of tetracycline. After 2 hours, an obvious binding 
between SPOP and Cul3 was observed, as detected by Cul3-V5 
immunoprecipitation. If CSN-mediated deneddylation would indeed promote 
the substrate receptor exchange, a slower rate would be detected in the 
binding of SPOP and Cul3 upon CSN siRNA knockdown compared to the 
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control. However, knockdown of CSN5 resulted in no significant difference 
in the apparent rate with which SPOP bound to Cul3 compared to the 
control. This result suggests that CSN-mediated deneddylation does not 
regulate the exchange of Cul3-bound substrate receptors with SPOP.   
 
     
FIGURE 4.13: Cells grown in 60-mm dishes were transfected with negative 
control or CSN5 siRNA, which was followed after 1 day by transfection of 
Cul3-V5 and FLAG-SPOP (in a tetracycline-inducible plasmid). Three days 
after siRNA transfection, 1 μg/ml tetracycline was added at time zero and 
cells were lysed at the indicated times; this was followed by V5 
immunoprecipitation and Western blotting of immunoprecipitates and cell 
lysates with the indicated antibodies.  
  
 
4.1.4.6 Role of CAND1 in promoting the exchange of the Cullin3 
substrate receptor SPOP 
Next, we tried to determine whether the CAND1-cullin binding 
upon CSN-mediated deneddylation promotes the substrate receptor 
exchange. We used the same approach as described previously but under a 
CAND1 siRNA knockdown condition. If the model assumption is true in 
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which the CAND1-cullin binding upon CSN-mediated deneddylation 
promotes the exchange of substrate receptors in the CAND1 cycle, the 
binding rates of Cul3-SPOP would be slower upon CAND1 siRNA 
knockdown. However, as shown in Figure 4.14, knockdown of CAND1 did 
not show any effect on the apparent rate with which SPOP bound to Cul3. 
This suggests that CAND1 binding to Cul3 upon CSN-mediated 
deneddylation does not regulate the exchange of Cul3-bound substrate 
receptors with SPOP. Thus, our results suggest that in our experimental 
system, both CSN-mediated deneddylation in the CSN cycle and the 
CAND1-cullin binding upon CSN-mediated deneddylation in the CAND1 
cycle do not enhance the substrate receptor exchange.  
 
               
FIGURE 4.14: Cells grown in 60-mm dishes were transfected with negative 
control or CAND1 siRNA, which was followed after 1 day by transfection of 
Cul3-V5 and FLAG-SPOP (in a tetracycline-inducible plasmid). Three days 
after siRNA transfection, 1 μg/ml tetracycline was added at time zero and 
cells were lysed at the indicated times; this was followed by V5 
immunoprecipitation and Western blotting of immunoprecipitates and cell 
lysates with the indicated antibodies. NS denotes nonspecific band. 
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Hypothesis 3: CSN prevents CAND1-mediated " CRL disassembly 
 
4.1.4.7 CSN does not function to prevent binding of CAND1 to Cul1 
In contrast to the previous hypothesis in which the mechanism of 
CSN-mediated cullin deneddylation transits CRLs into the CAND1 cycle and 
promotes the binding of CAND1 to cullin, it is also possible that the CSN 
prevents CRLs from entering the CAND1 cycle. This may be due to 
competition between CSN and CAND1 for overlapping binding sites in 
cullin proteins. Therefore, we tested whether the interaction of CSN with 
cullins prevents the binding of CAND1 to cullin proteins and consequently 
CAND1-mediated disassembly of the CRL complex. To test this hypothesis, 
we measured the effect of CSN5 siRNA knockdown on the interaction 
between Cul1 and CAND1. As shown in Figure 4.15, silencing of CSN5 did 
not affect the amount of CAND1 bound to Cul1. This result shows that CSN 
does not function to prevent the CAND1-cullin binding. Therefore, the 
interaction of CSN with cullin is unlikely to block the CRL complex from 
entering the CAND1 cycle.  
 
                                   
 
FIGURE 4.15: Role of CSN in preventing CAND1-mediated CRL 
disassembly. Cells were transfected with negative control or CSN5 siRNA, 
which was followed after 1 d by transfection of Cul1-V5. Cells were lysed 3 
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d after siRNA transfection, and cell lysates were subjected to V5 





4.1.5 Cullin neddylation promotes CSN binding to cullin proteins in vivo. 
Based on the CRL activation cycle, it is possible that cullin 
neddylation promotes the recruitment of CSN to CRLs. According to this 
cycle, binding of a substrate to the CRL complex leads to promotion of cullin 
neddylation. Subsequently, the neddylated CRL complex ubiquitinates the 
substrates and recruits the CSN multisubunit complex. Therefore, we 
considered the possibility that CSN interacts with CRLs during cullin 
neddylation. To test this, we used the specific inhibitor of cullin neddylation 
MLN4924 (Soucy et al, 2009) to investigate the interaction of CSN with 
cullin upon inhibition of cullin neddylation. First, cells with stable 
expression of FLAG-CSN5 were transfected with Cul1-V5. 3 μM of 
MLN4924 was then added to the cells for 3 hours before cell lysis. Cell 
lysates were collected for V5 immunoprecipitation, followed by Western 
blotting. As shown in Figure 4.16, a marked decrease was observed in the 
CSN5-Cul1 binding when cullin neddylation was inhibited (MLN4924 
treatment). This suggests that cullin neddylation is likely to mediate the 
binding of CSN to CRL in vivo. 
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FIGURE 4.16: Cells with stable expression of FLAG-CSN5 were 
transfected with Cul1-V5 and treated with 3 μM MLN4924 for 3 h, as 
indicated. Cell lysates were used for V5 immunoprecipitation, which was 




4.1.6 Induction of Cullin deneddylation causes CSN Dissociation from  
              the CRL complex. 
 
To further confirm the previous hypothesis that CRL neddylation is 
involved in the recruitment of CSN to CRL, we tried to inhibit cullin 
neddylation with an alternative approach in which we rapidly depleted the 
cellular ATP concentration (co-treatment of iodoacetate and myxothiazol). 
We also used the neddylation site mutant of Cul1 (K720R) in this 
experiment. As shown in Figure 4.17, the neddylated form of the K720 Cul1-
V5 mutant  disappeared when the neddylation site of Cul1 had been mutated. 
Although this K720 Cul1-V5 mutant reduced CSN5 binding to Cul1 
compared to wild type Cul1-V5 at time zero, no further decrease was 
observed in the binding of CSN and (K720R) upon the cellular ATP 
depletion. However, with the wild type Cul1-V5, the neddylated form of 
Cul1 was decreased upon the cellular ATP depletion. In addition, the binding 
of CSN5 to wild type Cul1-V5 was decreased to the same basal level as 
detected in the K720 Cul1-V5 upon the cellular ATP depletion. This result 
suggests that inhibition of cullin neddylation could block the binding of CSN 
to CRLs. It is possible that CSN has a preferential binding affinity to 
neddylated cullins.  
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FIGURE 4.17: Cells with stable expression of FLAG-CSN5 were 
transfected with wild-type or K720R mutant Cul1-V5 and subjected to 30 
min of myxothiazol (1 μM) and iodoacetate (2.5 mM) treatment, indicated as 





4.1.7 CSN5 preferentially binds to neddylated Cul1. 
 
To verify that CSN shows preferential binding to neddylated cullins, 
we used a CSN mutant in which the deneddylation activity is abrogated 
(D151N CSN5) and determined its binding to the endogenous Cul1 protein. 
First, the D151N CSN5 mutant and the wild type CSN5 were 
immunoprecipitated from HEK293T cell lysates and the binding of 
endogenous Cul1 was determined by Western blotting of 
immunoprecipitates. As shown in Figure 4.18, only the unneddylated form of 
endogenous Cul1 was detected with wild-type CSN5. This may be due to 
CSN- mediated deneddylation that removes the Nedd8 molecule from the 
cullin protein. In contrast to wild type, the D151N CSN5 mutant 
coimmunoprecipitated approximately equal amounts of neddylated and 
unneddylated Cul1. Because the neddylated form of Cul1 is very low 
abundant in the cell lysate, this result suggests that CSN5 has a preferential 
binding to neddylated Cul1. This result is also consistent with the hypothesis 
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that cullin neddylation promotes the binding of CSN to CRL. As a result, we 
propose that CSN binds preferentially to neddylated cullins.  
                                  
FIGURE 4.18: Cells were transfected with wild-type or D151N mutant 
FLAG-CSN5, which was followed by FLAG immunoprecipitation and 
Western blotting of immunoprecipitates and cell lysates with Cul1 and 





4.1.8 Cul2 and Cul3 C-terminal deletion mutants with constitutively   
active conformation show increased CSN binding in the absence of   
  neddylation 
 
Next, we tried to determine whether the CSN binding is dependent 
on cullin neddylation directly or indirectly via the consequence of the 
Nedd8-induced conformational change in the CRL C terminus (Duda et al., 
2008). Here, we used extreme C-terminal deletion mutants of Cul2 and Cul3 
which no longer can be neddylated. However, they harbor a constitutively 
active conformation that is able to mediate substrate ubiquitination in the 
absence of neddylation in vitro and in vivo (Duda et al., 2008; Yamoah et al., 
2008; Boh et al., 2011). As shown in Figure 4.19, even though the 
neddylated form of both C-terminally truncated Cul2 and Cul3 was absent, 
these proteins bound more to CSN2 and CSN5 compared to wild type, full 
length Cul2 and Cul3. This suggests that the binding of CSN to the 
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neddylated form of cullin is due to the Nedd8-induced conformational 
change in the CRL complex. Therefore, this shows that the conformational 
change that is mediated by cullin neddylation may be important for CSN 
binding. 
                            
FIGURE 4.19: Cells were transfected with expression constructs for the 
full-length or extreme C-terminal deletion mutants of Cul2 and Cul3, as 
indicated at the top of each panel. Subsequently, this was followed by V5 
immunoprecipitation. Imunoprecipitates and aliquots of the cell lysates were 
analyzed by Western blotting with with CSN2, CSN5 and V5 antibodies. 





4.1.9 Preferential binding of CSN to active CRLs is not a consequence of  
  increased amounts of bound polyubiquitinated substrates.  
 
CRL complexes with an active conformation are more efficient in 
mediating the polyubiquitination of substrate proteins. Hence, it is possible 
that CSN is recruited to the CRL complex via the polyubiquitin chain of the 
substrate protein. To determine whether the binding of CSN to active CRLs 
is dependent on the bound polyubiquitinated substrates, we transfected the 
cells using the S53A/F54A/E55A (SFE) Cul3 mutant (Cul3(SFE) mutant). 
This mutant is unable to bind to BTB substrate-receptor proteins and hence 
cannot recruit substrates for polyubiquitination. As a consequence, this 
mutant also exhibits a marked reduction in the neddylation level (Chew and 
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Hagen, 2007). As shown in Figure 4.20, preventing substrate binding to wild 
type Cul3 reduces neddylation and CSN5 binding. However, the 
constitutively active Cul3 C-terminal deletion mutant (Cul3 SFE (1-720aa) 
mutant) showed a markedly increased CSN5 binding compared to wild type 
Cul3. Thus, this result suggests that preventing substrate binding to 
constitutively active truncated Cul3 (Cul3 SFE (1-720aa) mutant) does not 
reduce CSN5 binding.  Therefore, this indicates that CSN binding to Cul3 is 
not directly dependent on substrate recruitment and polyubiquitination. 
Taken altogether, these results reveal that the CSN complex preferentially 
binds to the active form of CRL complexes. 
                      
 
FIGURE 4.20: Cells were transfected with expression constructs for the 
full-length or extreme C-terminal deletion mutants of Cul3, as indicated at 
the top of each panel. The SFE mutant of Cul3 corresponds to the 
S53A/F54A/E55A mutant of Cul3, which is unable to bind to substrate-
receptor subunits. The cells were lysed, and the lysates were subjected to V5 
immunoprecipitation (IP), Immunoprecipitates and aliquots of the cell lysates 








The ability of CSN to remove Nedd8 (deneddylation) from CRLs 
has emerged as a major mechanism to regulate the CRL activity. In vitro, 
CSN-mediated deneddylation can change the CRL complex from an active to 
an inactive form, thereby inhibiting CRL activity. Therefore, this suggests 
that CSN serves as a negative regulator in vitro. However, in vivo, CSN-
mediated deneddylation plays a positive regulatory role and promotes CRL 
activity. Based on this, it has been suggested that both neddylation and 
deneddylation are required for the CRLs to function under in vivo conditions. 
It has also been proposed that in vivo neddylation is highly dynamic (Cope 
and Deshaies, 2003). In the current study, we have provided support for this 
hypothesis. Based on the presented data, the Cul1 deneddylation rate was 
relatively fast as meaured either through ATP depletion or MLN4924 
inhibitor treatment. Both the ATP depletion and the MLN4924 inhibitor 
markedly reduced the neddylated form of cullin within 10 minutes. This 
suggests that the cells undergo a rapid neddylation and deneddylation 
process. Therefore, we conclude that the hypothesis of a highly dynamic 
regulation of cullin neddylation in vivo is likely to be true. 
Based on the dynamic neddylation and deneddylation in vivo, a 
CRL neddylation/deneddylation activation cycle has been proposed. 
According to this, the first step consists of binding of a substrate to the 
unneddylated form of the CRL (inactive condition). Substrate binding 
induces cullin neddylation and this activates the CRL complex. 
Subsequently, the substrate is being ubiquitinated and dissociates from the 
CRL complex. To switch back to the inactive condition of CRL, CSN would 
! 73!
remove Nedd8 from the CRL complex. The CRL activation cycle resumes 
when a new substrate binds to the CRL complex again. Therefore, it can be 
hypothesized that CSN-mediated deneddylation is coupled to substrate 
ubiquitination. In the present work, several independent experimental 
approaches that were used to examine this hypothesis. Our results showed 
that cullin deneddylation is not coupled to the substrate ubiquitination. 
However, one shortcoming of our study was that no specific inhibitor of 
substrate ubiquitination was available. Hence, we had to use less specific or 
indirect means to manipulate substrate ubiquitination, such as ATP depletion, 
treatment with the proteasome inhibitor MG-132 (which will lead to the 
accumulation of polyubiquitinated substrates and potentially an increase in 
substrate-CRL interaction) and enhancement of substrate ubiquitination 
through overexpression of the cdc34 E2 ubiquitin conjugating enzyme. Our 
results indicated that these manipulations did not cause any changes in the 
deneddylation rate. Taken altogether, we concluded that cullin deneddylation 
is unlikely to depend on the substrate ubiquitination. However, a definitive 
answer will require the availability of a specific ubiquitin E1 activating 
enzyme inhibitor. 
It has also been proposed that CSN modulates CRL activity through 
switching of the CRL complex between CSN and CAND1 cycles (Schmidt et 
al., 2009). In the CSN cycles, the neddylated form of CRL recruits a 
substrate for ubiquitination. After the substrate is ubiquitinated, it dissociates 
from the CRL complex. CRL would then undergo CSN-mediated 
deneddylation. When the CRL complex is in the absence of a substrate and 
bound Nedd8, the CRL complex prompts to enter the CAND1 cycle. In the 
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CAND1 cycle, the substrate receptor is released from the CRL complex upon 
recruiting of the CAND1 protein. Subsequently, CAND1 is being released 
from the cullin protein and a new substrate receptor is recruited to the cullin. 
Based on this model, it has been proposed that CSN-mediated cullin 
deneddylation in the CSN cycle facilitates the substrate-receptor exchange in 
the CAND1 cycle. In the current study, our data suggest that CSN-mediated 
deneddylation does not mediate the substrate receptor exchange. In addition, 
our data showed that the CAND1-cullin binding upon CSN-mediated 
deneddylation does not promote the substrate receptor exchange. However, 
our results are at variance with recently published studies (Pierce et al., 2013, 
Wu et al., 2013, Zemla et al., 2013). These studies reported that CAND1 
functions in as an F-box protein exchange factor. It is possible that our study 
did not come to the same conclusion because the dynamics of substrate 
receptor binding upon tetracycline dependent gene expression are too slow. It 
is also possible that the SPOP substrate receptor that was studied in our 
experiments does not require CAND1 as an exchange factor. 
As mentioned above, the binding of a substrate to the unneddylated 
form of CRL complex induces cullin neddylation and this in turn promotes 
substrate ubiquitination. The substrate induced neddylation has recently been 
shown to be due to displacement of CSN by the substrate through steric 
effects (Emberley et al, 2012). After the substrate has dissociated from the 
CRL complex, CSN can bind again to the CRL complex. In our study, we 
considered the possibility that CSN interacts preferentially with CRLs when 
they are in the neddyated state. Such a mechanism would facilitate the 
neddylation and deneddylation cycle. In our current study, several evidences 
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have been shown to support this hypothesis. First, a marked decrease was 
observed in the association of CSN5 and Cul1 upon MLN4924 treatment 
when cullin neddylation is inhibited specifically. Second, the binding of CSN 
to wild type Cul1 was also shown to decrease upon ATP depletion (resultung 
in inhibition of cullin neddylation).  Third, the basal level of the CSN5-Cul1 
binding was reduced when we used the neddylation site mutant of Cul1 
(K720R) and there was no further decreased upon ATP depletion. Therefore, 
we suggested that cullin neddylation is likely to promote CSN binding to the 
CRL complex.  
Based on the results showing that cullin neddylation enhances CSN-
cullin binding, we next hypothesized that CSN has a preferential binding to 
neddylated cullins. Indeed, our results using the D151N CSN5 mutant 
confirm this hypothesis. We also showed that the reason why CSN exhibits 
preferential binding to neddylated cullins is likely due to a conformational 
change of the cullin protein that is induced by the Nedd8 modification. Thus, 
this conformational change in the cullin C-terminus/Rbx1 structure upon 
neddylation leads to recruitment of the CSN complex, which may in turn 














  Chapter Two:  

















 It is known that the Cullin Ring Ligase (CRL) 3 recognizes and 
targets various important substrates for degradation (Furukawa et al., 2003; 
Pintard et al., 2003). CRL3 targeted substrates are generally involved in cell 
cycle regulation, cell migration, retrograde trafficking and antioxidant 
response. Inhibition of any components in the CRL3 has been shown to 
cause early embryonic lethality in mice. In addition, CRL3 deregulation has 
been revealed to inhibit cell migration in human and drosophila cells (Chen 
et al., 2009; Liu et al., 2009). This is due to accumulation of the CRL3 
substrate RhoA, which is involved in the regulation of actin cytoskeleton 
stress fiber formation  (Chen et al., 2009). 
The CRL3 complex consists of three main components: a Cul3 
protein, a RING domain protein and a substrate receptor protein. The Cul3 
protein binds the RING domain protein Rbx1 via its C-terminus. Rbx1 is 
responsible for the recruitment of the ubiquitin-charged E2 enzyme. 
However, the Cul3 substrate receptor protein is slightly different from other 
CRLs because it does not have a separate adaptor protein. All Cul3 substrate 
receptor proteins consist of a “Bric a brac, Tram-track and Broad 
Complex/Pox virus and Zinc finger” (BTB/POZ) domain. The Cul3 substrate 
receptor proteins also contain various substrate binding domain such as Zinc 
Finger, Kelch, MATH and Ras homology domains to form various CRL3 
BTB complexes. Thus, numerous CRL3 BTB complexes can target a large 
number of substrates for ubiquitination. Similar to other CRLs, the CRL3 
ubiquitination activity is first activated via a conjugation of the ubiquitin-like 
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protein Nedd8 onto the Cul3 C-terminal lysine residue. This Nedd8 
conjugation is mediated through the Nedd8-specific E1 APPBPA-Uba1 
heterodimeric enzyme and the E2 enzyme Ubc12. Nedd8 functions to 
activate CRLs by causing a conformational change in the cullin C-
terminus/Rbx1 structure. This results in an increase in Rbx1 flexibility. Thus, 
the ubiquitin charged E2-conjugating enzyme on the Rbx1 protein and the 
target substrate are brought into a close proximity.  
Keap1 and SPOP are the best characterized Cul3 BTB substrate 
receptors. The Keap1 and SPOP substrate receptors bind their substrates 
through a Kelch repeat domain and a MATH domain, respectively. It has 
been shown that the Cul3 BTB substrate receptors form homodimers through 
their BTB domains. For some CRL3 members, it has also been shown that 
BTB protein dimerization is essential for substrate recruitment. For instance, 
the Keap1 homodimer recruits the Nrf2 substrate through recognizing two 
different motifs, ETGE and DLG in Nrf2, thereby positions the Nrf2 
substrate in an appropriate orientation. The ETGE motif acts as a ‘hinge’ 
whereas the DLG motif acts as a ‘latch’ to clutch onto Keap1. The ETGE 
and DLG motifs are responsible for mediating the high and low affinity 
binding between Nrf2 and Keap1, respectively. Disruption of either the 
ETGE or DLG motif in Nrf2 would prevent its binding to Keap1 and thereby 
inhibits the Nrf2 ubiquitination. Under normal conditions, Nrf2 is maintained 
at a low basal level via the constitutively ubiquitination by the CRL3-Keap1 
complex. Under oxidative stress, the CRL3-Keap1 activity is suppressed. 
Thereby, the ubiquitination Nrf2 is inhibited. Thus, the Nrf2 substrate 
translocates into nucleus and activates the antioxidant transcriptional 
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response. 
The SPOP substrate receptor has also been shown to homodimerize 
to recruit its substrate Jun kinase phosphatase Puckered (PUC) for 
ubiquitination. This PUC substrate binds to the SPOP homodimer via 
multiple SPOP-binding sites. In the proposed SPOP dimer model, the SPOP 
homodimer has been shown to recruits the PUC substrate through the two 
flexibly orientated substrate-binding sites in the SPOP MATH domains. 
Thus, this suggests that homodimerization of Cul3 substrate receptors plays 
an important role in recruiting substrates for ubiquitination. 
 In addition to Cul3 substrate receptors, various Cul1 substrate 
receptors have also been shown to form dimers. Cdc4, a yeast Cul1 substrate 
receptor, homodimerizes to form a Skp1-Cul1-F-box(SCF)Cdc4 dimer 
complex. It has been shown that SCFCdc4 dimerization is important for 
substrate ubiquitination activity. This is likely due to the fact that the dimeric 
SCF complex may provide a bivalent geometry that contains two docking 
sites for the ubiquitin-charged E2 enzyme. Thus, this may optimize the 
ubiquitin transfer activity. 
For the CRL3 complex, two Cul3 dimerization models have been 
proposed. Firstly, the formation of a Cul3 dimer complex is indirect and 
mediated via BTB substrate receptor homodimerization (Chew et al., 2007).  
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Figure 5A. The structure of CRL3 dimer. Two Cul3 proteins (yellow) 
dimerize via the BTB domain (purple) in the Cul3 substrate receptors: Keap1 
or SPOP (blue).  
 
 Secondly, Wimuttisuk and Singer (2007) reported a different 
mechanism of Cul3 dimerization. According to this model, two Cul3 proteins 
dimerize directly via interaction of the C-terminal WH-B domain, as shown 
in Figure 5B. Based on this model, the BTB domain-containing proteins are 
not required for this Cul3 dimerization. It has also been proposed that the 
Cul3 dimer contains one Nedd8-modified Cul3 and one unmodified Cul3 
molecule. 
                   
Figure 5B. Model structure of CRL3 dimer. CRL3 dimerization is mediated 
via the Cul3 C-terminus. CRL3 dimer contains one neddylated Cul3 and one 
unneddylated Cul3 molecule.   
 
 In the current study, we tried to resolve the controversy over the two 
models by investigating the mechanism of Cul3 dimerization in mammalian 
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cells. We also tried to investigate what the Cul3 protein proportion is that 



















5.1.1 Cul3 mutants that are unable to bind to the BTB substrate                      
              receptor protein exhibit markedly reduced Cul3-Cul3 association 
 
It has been reported that CRL3 dimerization is important for the 
recognition and recruitment of numerous substrates for ubiquitination. Two 
different models of the Cul3 dimer complex have been proposed to explain 
this dimerization mechanism. According to Chew et al. (2007), it has been 
suggested that the Cul3 dimer complex formation is indirect and mediated 
via the association of the BTB substrate receptor proteins. However, 
Wimuttisuk and Singer (2007) that two Cul3 proteins dimerize directly via 
interaction of the C-terminal WH-B domain. Based on this model, the BTB 
domain-containing proteins are not required for Cul3 dimerization. To 
resolve this controversy, we used the same mutants as reported in Chew et al 
(2007) and Wimuttisuk and Singer (2007), the Cul3 S53A/F54A/E55A 
mutant (Cul3(SFE)) and the Cul3 L52AE55A mutant (Cul3(LE)), 
respectively. These two mutants were reported previously to be unable to 
bind to the BTB substrate receptor proteins. Thus, we compared the binding 
of these two different Cul3 mutants to wild type Cul3 using a 
coimmunoprecipitation assay. As shown in Figure 5.1, compared to wild 
type Cul3, both the Cul3(SFE) and the Cul3(LE) mutants were found to 
exhibit decreased homodimerization. The Cul3(LE) mutant exhibited a 
slightly higher remaining binding affinity compared to wild type Cul3. This 
result suggests that the association of Cul3 with the BTB substrate receptor 
proteins is essential for Cul3-Cul3 binding.  
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Figure 5.1 HEK293 cells were transfected in 60-mm cell culture plates for 2 
days with expression constructs for the proteins indicated at the top of each 
panel. The cells were lysed, and the lysates were subjected to V5 
immunoprecipitation (IP) and aliquots of the cell lysates were analyzed by 
Western blotting with the indicated antibodies.  
 
5.1.2 Cul3 mutants exhibit reduced binding to Keap1 in HEK293T cells  
  To validate that the two Cul3 mutants are unable to bind to the 
BTB substrate receptor proteins, we performed co-immunoprecipitation 
essays on the Cul3 mutants to determine their binding affinity to the BTB 
substrate receptor proteins, SPOP and Keap1.  As shown in Figure 5.2, there 
was no significant binding of both the Cul3(LE) and Cul3(SFE) mutants to 
the SPOP protein compared to a strong binding between wild type Cul3 and 
SPOP. A marked decreased was also noted in the binding of Cul3(SFE) to 
Keap1 (Figure 5.3) compared to the binding of wild type Cul3 to Keap1. 
However, the binding of Cul3(LE) with Keap1 was only found to slightly 
decrease compared to wild type Cul3. Therefore, this suggests that Cul3(LE) 
and Cul3(SFE) mutants have different affinities to Keap1. Thus, this may 
explain why binding between Cul3 and Cul3(LE) was still observed in the 
study by Wimuttisuk and Singer (2007).   
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Figure 5.2 The cells were transfected in 60-mm cell culture plates for 2 days 
with expression constructs for the proteins indicated at the top of each panel. 
The cells were lysed, and the lysates were subjected to V5 
immunoprecipitation (IP) and aliquots of the cell lysates were analyzed by 
Western blotting with the indicated antibodies.  
 
           
Figure 5.3 The cells were transfected in 60-mm cell culture plates for 2 days 
with expression constructs for the proteins indicated at the top of each panel. 
The cells were lysed, and the lysates were subjected to V5 
immunoprecipitation (IP) and aliquots of the cell lysates were analyzed by 
Western blotting with the indicated antibodies.  
 
 
5.1.3 Cul3-Cul3 binding is independent of the WH-B domain  
 
According to the Cul3 dimer complex model proposed by Wimuttisuk 
and Singer, 2007, dimerization of a CRL3 complex is mediated via the 
hydrophobic residues in the Winged-Helix B (WH-B) domain near the Cul3 
C-terminus. Thus, based on this model, only the Cul3 C-terminus but not the 
Cul3 N-terminus is required for the CRL3 dimerization. To test whether the 
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WH-B domain is involved in the CRL3 dimerization, a C-terminal deletion 
construct of Cul3 that contains only 1-427 amino acids (Cul3(1-427)) was 
generated. This Cul3(1-427) construct excludes the WH-B domain in human 
Cul3. We performed co-immunoprecipitation assays to measure its 
interaction with wild type Cul3. As shown in Figure 5.4, a significant 
interaction between Cul3(1-427) and wild type Cul3 was observed. This 
suggests that WH-B domain which exists near the Cul3-C-terminus is not 
essential for the CRL3 dimerization. 
 
                       
 
Figure 5.4 The cells were cotransfected with Cul3-HA and Cul3(1-427)-V5 
(ΔCT), as indicated at the top of each panel. The cells were lysed, and the 
lysates were subjected to V5 immunoprecipitation (IP), Immunoprecipitates 
and aliquots of the cell lysates were analyzed by Western blotting with the 
indicated antibodies.  
 
 
5.1.4 Cul2(NT)-Cul3(CT)-V5 is protected from the proteasome 
dependent degradation 
To further confirm the previous data that the Cul3 C-terminal WH-
B domain in not involved in the Cul3-Cul3 interaction, we next generated an 
N-terminal deletion of Cul3 which contains only 392-768 amino acids. This 
construct contains the WH-B domain. This truncated Cul3 protein, however, 
was not well expressed. This may be because this N-terminally deleted Cul3 
is not stable and is being degraded by the 26S proteasome. Indeed a 
! 86!
significant accumulation of the Cul3(CT) was observed upon proteasome 
inhibition with MG-132 (Figure 5.5). Hence, a fusion construct that consists 
of the C-terminus of Cul3 (amino acid 392-768), fused to the N-terminus of 
Cul2 (amino acid 1-394) was generated. The rationale for this approach was 
that the Cul2 N-terminus would confer protein stability while being unable to 
engage with Cul3 substrate receptor proteins. The fusion construct also 
carries a C-terminal V5-tag (Cul2(NT)-Cul3(CT)-V5) for 
immunoprecipitation. As shown in Figure 5.5, the Cul2(NT)-Cul3(CT)-V5 
fusion protein did not increase when MG-132 was added to the cells. Hence, 
this protein is unlikely to be subject for proteasome dependent degradation. 
Given its much better expression compared to the truncated Cul3(CT)-V5 
construct, we thus used the Cul2(NT)-Cul3(CT)-V5 fusion construct to 
further investigate the involvement of the Cul3 C-terminus in the Cul3-Cul3 
association.  
                          
 
Figure 5.5 The cells were transfected with wild type (wt) Cul3-V5, 
Cul3(CT)-V5 and Cul2(NT)-Cul3(CT)-V5, as indicated. Two days after 
transfection, the cells were treated with 25 μM MG-132 for 6 hours, where 
indicated, and then lysed, followed by Western blotting of cell lysates with 







5.1.5 Cul3 N-terminus is necessary for Cul3-Cul3 binding  
To determine whether the Cul3 C-terminus is required for Cul3-
Cul3 association, we measured the binding of wild type Cul3 and fusion 
Cul2(NT)-Cul3(CT)-V5 via co-immunoprecipitation assays. As shown in 
Figure 5.6, a significant interaction was observed between wild type Cul3-
V5 and a full length Cul3-HA. However, there was no interaction between 
the Cul2(NT)-Cul3(CT)-V5 fusion protein and the full length Cul3-HA. 
These results suggest that the Cul3 N-terminus is important for Cul3-Cul3 
association. In addition, this also supports the hypothesis that the BTB 
substrate receptor proteins are required for the Cul3-Cul3 binding. This is 
because the Cul3 N-terminus is responsible in recruiting the BTB substrate 
receptor proteins. In contrast, the WH-B domain that exists at the Cul3 C-
terminus is unlikely to play a role in Cul3-Cul3 association. Therefore, we 
suggest that the Cul3 N-terminus and not the Cul3 C-terminus is necessary 
for Cul3-Cul3 binding. 
 
              
    
Figure 5.6 HEK293 cells were transfected in 60-mm cell culture plates for 2 
days with expression constructs for the proteins as indicated at the top of 
each panel. The cells were lysed and the cell lysates were subjected to V5-





5.1.6 Mutation of the neddylation site in Cul3 does not affect Cul3 
dimerization 
According to the CRL3 dimer complex model proposed by 
Wimuttisuk and Singer, 2007, the Nedd8 small ubiquitin-like protein is 
essential for Cul3 dimerization. The CRL dimer complex contains one 
neddylated Cul3 and one unneddylated Cul3. To validate this, we measured 
the binding affinity between the neddylation site mutant of Cul3 (K712R) 
and wild type Cul3 via co-immunoprecipitation essays. However, as shown 
in Figure 5.7, two Cul3 (K712R) mutants showed same level of binding as 
compared to the binding between K712R mutant and wild type Cul3.  This 
result suggests that culllin neddylation is not essential in mediating CRL3 
dimerization.  
 
                                  (Longer exposure) 
 
Figure 5.7 The cells were cotransfected with Cul3(K712R)-HA and wild 
type Cul3-V5 or Cul3(K712R)-V5 as indicated at the top of the panel. The 
cells were lysed and the lysates subjected to V5 immunoprecipitation (IP). 
Immunoprecipitates and aliquots of the cell lysates were analyzed by 






5.1.7 Cullin neddylation is not involved in Cul3-Cul3 binding 
 
To further validate the hypothesis that cullin neddylation is not 
required for Cul3 dimerization, a HEK293 cell line with tetracycline-
inducible expression of dominant negative, C111S mutant Ubc12 (dnUbc12) 
was used. Ubc12 is a Nedd8 E2 enzyme, involved in recruiting Nedd8 from 
the Nedd8 E1 enzyme and transferring the Nedd8 protein onto the substrate 
(see previous chapter). In the experiment in Figure 5.8, Cul3-V5 and Cul3-
HA were first co-transfected into dnUbc12 cells. The expression of dnUbc12 
was then induced using tetracycline. The Cul3-Cul3 binding was measured 
using co-immunoprecipitation assay. As expected, the neddylated form of 
Cul3 disappeared upon induction with tetracycline (Figure 5.8). No 
significant difference was observed in the Cul3-Cul3 binding between 
tetracycline induced and control cells. This result is consistent with the 
previous data in Figure 5.7. Taken together, these results suggest that cullin 
neddylation does not play a role in Cul3-Cul3 association.  
 
                        (Longer exposure) 
Figure 5.8 Cells with stable expression of dnUbc12 under control of a 
tetracycline-inducible promoter were transfected in 60-mm cell culture plates 
for 2 days with expression constructs for the proteins indicated at the top of 
each panel, followed by 1 μg/ml tetracycline treatment for 18 h, where 
indicated. The cell lysates were subjected to V5 immunoprecipitation (IP). 
Immunoprecipitates and aliquots of lysates were analyzed by Western 
blotting with the indicated antibodies.  
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5.1.8 Cul3-Cul3 binding is independent of cullin neddylation in vivo 
 
 We continue to investigate the involvement of the Nedd8 protein in 
Cul3-Cul3 binding by using an in situ proximity ligation assay. In these 
experiments, we co-transfected Cul3-V5 and Cul3-Flag into the dnUbc12 
cells and used tetracycline to induce the expression of dnUbc12. We used 
two different primary and secondary antibodies directed against the V5 and 
Flag epitode tags and performed the ligation assay. Fluorescence microscopy 
was used to detect the signal of each ligated pair of Cul3-V5-Cul3-Flag 
dimers (or multimers). As expected, the neddylated form of Cul3 was 
markedly reduced in the tetracycline induced cells (Figure 5.9). This was less 
obvious for the Cul3-V5 protein where the basal neddylation levels were 
low. As shown in Figure 5.10, in control cells and in cells induced with 
tetracycline, the amount of distinct fluorescent spots were qualitatively 
similar. Thus, this result further indicates that Cul3-Cul3 binding is 
independent of the Nedd8 modification.  
                                   
    
Figure 5.9 Cells with stable expression of dnUbc12 under control of a 
tetracycline-inducible promoter were transfected in 12-well cell culture 
plates for 2 days with expression constructs for the proteins indicated at the 
top of each panel, followed by 1 μg/ml tetracycline treatment for 24 hours, 
where indicated. Aliquots of the cell lysates were analyzed by Western 
blotting with the indicated antibodies.   
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Figure 5.10 Tet-on dnUbc12 cells were transfected in 12-well cell culture 
plates as indicated at the bottom of each panel. Cells were treated with 
1 μg/ml tetracycline for 24 h where indicated.  The cells are fixed and were 
subjected to in situ proximity ligation assay, as described under “Materials 
and Methods” and then viewed by fluorescent microscopy. As expected, 
fluorescent spots were only observed when Cul3-V5 and Cul3-FLAG were 
cotransfected, but not if Cul3-V5 or Cul3-FLAG were transfected alone. 
 
           
                
5.1.9 Two Cul3 proteins are involved in assembly of a CRL3-SPOP    
complex in vivo   
 
It has been shown that the recombinant SPOP protein forms a 2:2 
complex with Cul3/Rbx1 (Zhuang et al., 2009).  Based on this, the CRL3-
SPOP complex consists of two Cul3 proteins and two SPOP substrate 
receptor proteins. However, this stoichoimetry of the CRL3-SPOP complex 
has thus far not been shown in vivo.  To investigate the stoichoimetry of the 
CRL3-SPOP complex in cells, two differently tagged Cul3 proteins, Cul3-
HA and Cul3-V5, were co-transfected together with Flag-SPOP into 
HEK293T cells. The binding affinity between Flag-SPOP and Cul3-HA or 
Cul3-V5 was measured by using co-immunoprecipitation assay. 
Subsequently, the bound Cul3 complexes were eluted with Flag peptide. 
Another co-immunoprecipitation assay was performed to pull down Cul3-
HA that was bound to Cul3-V5 and Flag-SPOP. As shown in Figure 5.11, a 
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significant binding of both Cul3-V5 and Cul3-HA to Flag-SPOP was 
detected. This result suggests that in vivo, at least two Cul3 proteins are 
present in the CRL3-SPOP complex.  
 
Figure 5C. The structure of CRL3 dimer. Two differently tagged Cul3 
proteins, Cul3-V5 and Cul3-HA, were co-transfected together with Flag-
SPOP or Flag-Keap1 into HEK293T cells. The cells were lysed, and the 
lysates were subjected to Flag immunoprecipitation (IP) and eluted with Flag 
peptide. The Flag-SPOP or Flag-Keap1 complexes were then subjected to V5 
immunoprecipitation (IP). Immunoprecipitates and aliquots of the cell 
lysates were analyzed by Western blotting with the HA antibody  
 
           
 
Figure 5.11 The cells were transfected as indicated at the top of each panel. 
The cells were lysed, and the lysates were subjected to Flag 
immunoprecipitation (IP) and eluted with Flag peptide. The complexes were 
then subjected to V5 immunoprecipitation (IP). Immunoprecipitates and 
aliquots of the cell lysates were analyzed by Western blotting with the 
indicated antibodies. NS denotes a non-specific band and * non-specific 
binding of Cul3-HA. 
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5.2.0 Two Cul3 proteins are involved in assembly of a CRL3-Keap1 
    complex in vivo 
   
 In addition to the CRL3-SPOP complex, it has been shown that in 
the recombinant CRL3-Keap1 complex, only one Cul3 protein is bound to 
two Keap1. This has thus far also not been shown in cells. To determine the 
stoichoimetry of the CRL3-Keap1 complex in vivo, the same approach as 
described above for the CRL3-SPOP complex was used. Two differently 
tagged Cul3 proteins, Cul3-HA and Cul3-V5, together with Flag-Keap1 were 
first transfected into HEK293T cells. Subsequently, the Flag-Keap1 protein 
was immunoprecipitated using Flag agarose, followed by elution with Flag 
peptide to obtain the bound Cul3 complexes. V5-immunoprecipitation was 
then performed to pull down Cul3-HA that was bound to Cul3-V5 and Flag-
Keap1. As shown in Figure 5.12, both Cul3-V5 and Cul3-HA showed 
significant binding to Flag-Keap1. This result suggests that at least two Cul3 
proteins are involved in the CRL3-Keap1 complex formation in vivo. Thus, 
this reveals that under in vivo conditions, a CRL3 complex exists at least in a 
dimeric state. Hence, our data are not in support of the study by in Small et 
al. (2010). Taken altogether with the previous data, we propose that at least 
two Cul3 proteins are present in both the CRL3-Keap1 and the CRL3-SPOP 
complex in vivo. 
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Figure 5.12 The cells were transfected as indicated at the top of each panel. 
The cells were lysed, and the lysates were subjected to Flag 
immunoprecipitation (IP) and eluted with Flag peptide. The complexes were 
then subjected to V5 immunoprecipitation (IP). Immunoprecipitates and 
aliquots of the cell lysates were analyzed by Western blotting with the 
indicated antibodies. NS denotes a non-specific band.  
 
 
5.2.1 Estimation of the proportion of Cul3 that exists in multimeric    
    Cul3/Rbx1-BTB protein complexes in vivo   
 
Based on the results shown above the CRL3 complex exists at least 
in a dimeric state in vivo. However, the proportion of Cul3 proteins that 
exists as a dimer in vivo is not known. Thus, in further experiments we tried 
to quantify the percentage of Cul3 that exists in a self-associated form. Two 
forms of Cul3 with different molecular weights were used to differentiate 
them based on their mobility in SDS-PAGE gels. One form contains full 
length Cul3 carrying a C-terminal EGFP tag. The other form contains full 
length Cul3 carrying an N-terminal Flag tag. The N-terminal Flag was used 
for immunoprecipitation. Both forms of Cul3 proteins contain an HA tag at 
the extreme C-terminus to compare their abundance. To examine the Cul3 
proteins proportion that exists as a dimer or multimer in vivo, we first co-
transfected both Cul3 forms into HEK293 cells and subsequently 
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immunoprecipitated Flag-Cul3-HA using FLAG beads. We then compared 
the ratio of Cul3-EGFP-HA to Flag-Cul3-HA in the cell lysates (input) with 
the ratio in the immunoprecipitates (corresponding to dimeric Cul3 
Complex). In the representative experiment shown in Figure 5.13, the ratio 
of Cul3-EGFP-HA to Flag-Cul3-HA in the input (Rlysate; lane 6) was 0.53:1 
whereas the ratio of Cul3-EGFP-HA to Flag-Cul3-HA in the 
immunoprecipitates (RIP; lane 3) was 0.18:1. The percentage of Cul3-EGFP-
HA bound to Flag-Cul3-HA can be calculated as RIP/Rlysate x 100% and 
amounts to 34%. In addition to Flag-Cul3-HA, Cul3-EGFP-HA can also 
form a dimer with itself and with endogenous Cul3. The affinity of Cul3-
EGFP-HA to itself, Flag-Cul3-HA and endogenous Cul3 is expected to be 
identical. As mentioned above, the ratio of Cul3-EGFP-HA to Flag-Cul3-HA 
in the input (lane 6) was 0.53:1. It therefore follows that the percentage of 
Cul3-EGFP-HA that exists as a dimer with itself equals the percentage of 
Cul3-EGFP-HA/Flag-Cul3-HA dimer multiplied by 0.53, resulting in 18%. 
To estimate the amount of Cul3-EGFP-HA bound to endogenous Cul3, we 
determined the ratio of endogenous Cul3 to Flag-Cul3-HA by western 
blotting with Cul3 antibody. As shown in Figure 5.14, the ratio is 0.41:1. 
Therefore, the percentage of Cul3-EGFP-HA that exists as a dimer with 
endogenous Cul3 equals the percentage of Cul3-EGFP-HA/Flag-Cul3-HA 
dimer multiplied by 0.41, resulting in 14%. Adding the percentage of Cul3-
EGFP-HA bound to itself, to Flag-Cul3-HA, and to endogenous Cul3 
together results in a total of 66% of dimeric Cul3-EGFP-HA. These results 
suggest that approximately two thirds of cellular Cul3 protein exists in a 
tetrameric Cul3/Rbx1-BTB protein complexes in vivo.  
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Figure 5.13 The cells were transfected as indicated at the top of each panel. 
The cells were lysed and the lysates were subjected to Flag 
immunoprecipitation (IP). Immunoprecipitates and aliquots of the cell 
lysates were analyzed by Western blotting with the indicated antibodies. The 
quantification of the Western blot results for both immunoprecipitates and 
aliquots of the cell lysates was performed by digitization using the Odyssey 
Infrared Imaging system in the fluorescence intensity of 800CW, green. 
 
                                    
Figure 5.14 The cells were transfected as indicated at the top of each panel. 
The cells were lysed and the lysates were subjected to Flag 
immunoprecipitation (IP). Lysates were analyzed by Western blotting with 











In recent years, it has become more apparent that cullin dimerization 
is important in promoting ubiquitination activity. Among all the cullins, 
Cul1, Cul3 and Cul4A have been shown to exist as dimer, however 
dimerization of Cul2 and Cul5 remains unknown (Chew et. al, 2007). Based 
on a CRL computational modeling, it has been revealed that a dimer of two 
substrate adaptor subunits is able to assemble with two cullin proteins in a 
CRL complex (Stogios and Prive, 2004). In the SCFCdc4 complex, the Cdc4 
substrate receptor homodimerizes to assemble two Cul1 proteins together 
and thus forms a dimeric SCFCdc4 complex (Tang et al., 2007). Dimerization 
of the Cdc4 substrate receptor is mediated via the N-terminal D domain 
which contains a small conserved dimerization motif. Cdc4 
homodimerization is important in promoting the ubiquitination of SCFCdc4 
substrates such as phosphorylated Sic1. It has also been shown that a dimeric 
Cdc4 can promote the formation of a long polyubiquitin chain onto 
phosphorylated-Sic1 in a relatively fast manner compared to a monomeric 
Cdc4 even though both the monomeric and dimeric Cdc4 substrate adaptor 
subunits have equal binding affinities to this substrate. 
As mentioned above, in a structural model of the CRL3 complex, 
the BTB substrate receptor protein has been shown to mediate Cul3 
homodimerization (Stogios and Prive, 2004). In vivo, the Cul3-BTB-Kelch 
complex dimerization is mediated through the association of BTB domain-
containing proteins (Zipper and Mulcahy, 2002; Chew et. al., 2007). 
However, Wimuttisuk and Singer (2007) reported that Cul3 dimerization 
occurred in a different model. The authors suggested that two Cul3 proteins 
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dimerize via interaction of the C-terminal WH-B domains of Cul3 and the 
Cul3 dimer consists of one neddylated Cul3 and one unneddylated Cul3 
molecule (Wimuttisuk and Singer, 2007). Based on this CRL3 model, the 
BTB substrate receptors are not involved in mediating the Cul3 dimerization. 
However, in the current study, we provide several lines of evidence that 
homodimerzation of the BTB substrate receptor proteins is required for the 
CRL3 complex dimerization. We also found that the Cul3 dimerization does 
not depend on the Cul3 C-terminus which is in contrast to the study in 
Wimuttisuk and Singer, 2007. According to Wimuttisuk and Singer, 2007, 
disruption of Nedd8-Cul3 WH-B domain near the Cul3 C-terminus inhibited 
the Cul3-Cul3 association. This suggests that Cul3-C-terminal is important in 
mediating Cul3 dimerization. However, based on our results, the WH-B 
domain, which exists near the Cul3-C-terminus, is not essential for the CRL3 
dimerization. Our results also suggested that the formation of the Cul3 dimer 
depends on the Cul3 N-terminus and is independent of the Cul3 C-terminus 
and the WH-B domains.  
Furthermore, Wimuttisuk and Singer, 2007 proposed that the Cul3 
dimer consists of one Nedd8-modified Cul3 and one unmodified Cul3 
molecule (Wimuttisuk and Singer, 2007). This suggests that Cul3 
neddylation is important for Cul3 dimerization. However, we provide several 
lines of evidence showing that Cul3 dimerization is independent of Cul3 
neddylation. First, the binding affinity between the neddylation site mutant 
of Cul3 (K712R) and wild type Cul3 was the same as compared to the 
binding affinity between K712R Cul3 mutant.  Second, no significant 
difference was observed in the Cul3-Cul3 binding between the tetracycline 
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induced dnUbc12 cells (where neddylation is inhibited) and control cells. 
Third, based on the in situ proximity ligation result, the amount of distinct 
fluorescent spots, indicative of self-associated Cul3 complexes, were 
qualitatively similar in both the control cells and in the dnUbc12 cells 
induced with tetracycline. Thus, our results indicate that Cul3 dimerization is 
independent of Cul3 neddylation.   
It has been revealed that two Cul3 proteins are bound to two SPOP 
substrate receptors in a recombinant Cul3-SPOP complex (Zhuang et al., 
2009). However, Small et al (2010) provided evidence that in vitro, one Cul3 
protein is bound to a Keap1 homodimer in a Cul3-Keap1 complex (Small et 
al., 2010). In this study, we provided evidence that in vivo, at least two Cul3 
proteins are present in the Cul3-SPOP complex or in the Cul3-Keap1 
complex. Our results with the Cul3-Keap1 complex contradicts with the 
study by Small et al., 2010. This is likely due to the different expression 
system that was used in our experimental approach. Of note, it has been 
shown that a KLHL7 BTB substrate receptor mutant that can form a 
homodimer with wild type KLHL7 but is unable to bind to Cul3 inhibits the 
ubiquitination activity (Kigoshi et al., 2011). Thus, this suggests that two 
bound Cul3 proteins in a heterodimeric Cul3 ligase complex are important to 
target the substrate for ubiquitination Therefore, this result is in support of 
our findings that at least two Cul3 proteins are present in the Cul3-SPOP 
complex or in the Cul3-Keap1 complex. 
In a modeling study, Potassium channel tetramerization domain 
containing protein 11 (KCTD11), a BTB substrate receptor subunit, has 
! 100!
shown to form tetramers (Correale et al., 2011). The (KCTD11) tetramer 
structure comprises four Cul3 proteins. Thus, this raises the possibility of 
forming a tetrameric Cul3 E3 ubiquitin ligase. However, our study does not 
able to distinguish dimer or tetramer. Finding from our study showing that 
most of the in vivo Cul3 proteins exist as a dimer or multimer. Therefore, this 
may support that there is a possibility of forming a tetrameric Cul3 E3 ligase 
complex. Taken altogether with the evidence that we provided earlier, it is 
likely that the BTB substrate receptors play an important role in mediating 
Cul3 dimerization or multimerization. This Cul3 dimer or multimer may 


















Chapter Three:  
Identification and characterization of  










The SCF complex is the most well studied member among the 
CRLs. It consists of four main components: Skp1, Cul1, F-box protein 
substrate receptors, and the Rbx1 RING finger protein. SCF E3 ligases play 
an important role in maintaining cell cycle regulation. Deletion or mutation 
of any components (Skp1, Cul1, F-box protein or Rbx1) in the SCF complex 
has been shown to arrest the cell cycle. Each of the components contributes 
in a different way to the function of the SCF complex. Cul1, a member of the 
cullin protein family, serves as a scaffold protein to bridge Skp1 and Rbx1 
together. The Rbx1 RING domain protein is important for the recruitment of 
the ubiquitin-charged E2 enzyme to the SCF complex, mediating the 
ubiquitin transfer to the target substrate protein. Skp1 serves as an adaptor 
protein to link a variable F-box protein to the Cul1 N-terminus.    
There are approximately 70 F-box proteins that have been identified 
in mammalian cells (Jin et al., 2004). Each F-box proteins can assemble to 
form a specific SCF complex and recruit different substrates, contributing to 
the SCF specificity. In general, the F-box proteins can be divided into three 
classes. These are F-box and Leucine Rich Repeats (FbxL), F-box and 
WD40 (FbxW), and F-box and other domain (FbxO). These three classes of 
the F-box proteins contain an F-box motif and a substrate binding domain. 
One famous example for a FbxL class F-box protein is Skp2. The Skp2 F-
box protein assembles with Skp1, Cul1 and Rbx1 to form a SCFSkp2 complex. 
One of the well-known SCFSkp2 target substrates is p27Kip1 (hereafter referred 
to as p27) (Carrano et al., 1999). It has been shown that deletion or mutation 
! 103!
of Skp2 in the SCFSkp2 complex can cause the accumulation of cyclin-
dependent kinase inhibitor, p27. This would then lead to the deregulation of 
cell cycle progression. Overexpression of the Skp2 F-box protein has also 
been shown to cause poor tumor differentiation and survival in many cancer 
cell lines such as lung cancer cells.  
For the FbxW class F-box proteins, some of its members recognize 
specific recognition motifs in their substrates, such as the TPXX(X)S or the 
DSGXX(X)S recognition motif. A famous example of the FbxW class F-box 
proteins is FBW7 (F-box and WD repeat domain-containing 7). Similar to 
other F-box proteins, FBW7 also binds to Cul1, Rbx1 and Skp1 to form a 
SCFFBW7 complex. One of the well known SCFFBW7 substrates is cyclin E (Ye 
et al., 2004, Hao et al., 2007, Bhaskaran et al., 2013). It contains the 
TPXX(X)S motif to bind to the SCFFBW7 complex for degradation. 
Importantly, binding of FBW7 requires prior phosphorylation of the 
substrate at the threonine and serine in the TPXX(X)S motif. Dysfunction of 
the SCFFBW7 complex, e.g. through mutations in FBW7 as frequently 
observed in cancers, has been shown to lead to the accumulation of the 
cyclin E protein. It has been reported that the cyclin E accumulation leads to 
reduction in cell size and shortening of G1 phase. Another well-known 
FbxW class F-box protein is β-TrCP. One of its well-studied substrates, IκB, 
contains a DSGXX(X)S recognition motif to bind to the SCFβ-TrCP complex 
for ubiquitination. Similar to the FBW7 recognition motif, binding of β-
TrCP to its substrates requires phosphorylation of the two serine residues in 
the DSGXX(X)S motif. The IκB proteins normally binds and sequesters NF-
κB in the cytoplasm. Upon degradation of IκB, the NF-κB transcription 
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factor enters the nucleus and activates specific genes that are involved in the 
cellular survival response, in cell proliferation or the immune response. 
The FbxO class F-box proteins contain substrate-binding domains 
other than those previously described (Leucine Rich Repeats and WD40) or 
do not contain any recognizable substrate binding motifs. F-box only protein 
7 (FBXO7), one of the well characterized FbxO F-box proteins, contains a 
new substrate binding domain, proline-rich region (PRR), to recruit its 
substrate hepatoma-up-regulated protein (HURP) for ubiquitination (Hsu et 
al., 2004). Overexpression of HURP has been shown to regulate cell growth 
in various carcinomas including breast cancer, colon cancer, human 
hepatocellular carcinoma and transitional cell carcinoma.  FBXO7 has also 
been reported to be involved in the pathogenesis of parkinsonian-pyramidal 
disease (Reviewed in Deng et al., 2013). FBXO7 mutations, leading to loss 
of function of the SCFFBXO7 complex, is likely to be causally involved in 
parkinsonian-pyramidal disease. 
In recent years, numerous studies have shown that various SCF 
substrates identified are involved in a wide range of cellular activities, such 
as cell cycle progression, signal transduction and transcription. Given that 
there are approximately 70 different F-box proteins, of which only few have 
been well characterized, there are likely numerous new F-box protein 
substrates yet to be discovered. Identification and characterization of the new 
F-box substrate proteins are essential to provide a better understanding of the 
functional role of the SCF complex. A screening of SCF substrates which 
performed by Yen and Elledge, 2008 using Global Protein Stability (GPS) 
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Profiling has identified many proteins as candidate bona fide targets of the 
SCF (SKP1-cullin-F-box) ubiquitin ligase. GPS is a fluorescent-based 
reporter system that combines Fluorescent Activated Cell Sorting (FACS) 
with DNA microarray deconvolution to systematically examine changes in 
protein stability in live cells. In their approach to identify SCF substrates, the 
authors used a dominant-negtaive version of Cul1. However, the majority of 
the identified proteins has thus far not been confirmed. Furthermore, the 
ubiquitination of these substrates by SCF complexes has not been 
characterized and the specific F-box proteins responsible have not been 
identified. Therefore, based on the candidate substrate list obtained by GPS 
profiling as reported by Yen and Elledge (2008), we selected a number of 
substrates that contain the putative FBW7 or β-TrCP recognition motifs 
TPXX(X)S or DSGXX(X)S, respectively, for further characterization.  In the 
current study, we try to confirm whether these selected F-box protein 
substrates are new potential SCF substrate and study the mechanism and 












6.1.1 Flag-GKAP1 accumulates upon MLN4924 treatment  
To identify and characterize potential novel SCF substrates, we 
inspected the GPS profiling data reported by Yen and Elledge (2008). The 
primary selection criterion was the presence of DSGXX(X)S or TPXX(X)S 
phosphodegrons in the primary sequence of potential substrates. We also 
considered recognition motifs where the C-terminal serine was replaced by 
one or more acidic residues, as these have also been reported to mediate 
binding to β-TrCP and FBW7. One of the potential SCFβ-TrCP substrates on 
the GPS profiling list is G kinase anchoring protein 1 (GKAP1). This protein 
has been reported to be involved in germ cell development (Yuasa et al., 
2000). It contains a DSGXX(X)S substrate recognition motif. To validate 
whether GKAP1 is a SCF ubiquitin ligase substrate, a Flag tagged GKAP1 
plasmid was generated and first transfected into HEK293T cells. Cells were 
treated with the Nedd8 activating E1 enzyme (NAE) inhibitor MLN4924 for 
24 hours. As mentioned above, this inhibitor specifically inhibits cullin 
neddylation and leads to accumulation of CRL substrates. Cells were also 
treated with the protein synthesis inhibitor cycloheximide to determine if the 
protein is rapidly turned over as well as with MG-132 to confirm ubiquitin-
proteasome dependent degradation of GKAP1. As shown in Figure 6.1, the 
expression level of Flag-GKAP1 was increased upon the treatment of 
MLN4924. Surprisingly, the Flag-GKAP1 protein concentration also 
increased after cycloheximide compared to untreated cells. However, there 
was no significant difference after treatment with the proteasome inhibitor, 
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MG132. Thus, the increased level of Flag-GKAP1 upon MLN4924 treatment 
suggests that the protein is a CRL substrate. The lack of effect of MG-132 
could potentially be explained by the fact that MLN4924 is much more 
potent in inhibiting CRL substrate degradation compared to the proteasome 
inhibitor. However, the increase in Flag-GKAP1 levels upon cycloheximide 
treatment is unexpected.  
               
Figure 6.1 HEK293T cells transfected with Flag-Gkap1 were treated with 40 
μM cycloheximide (CHX) for 6 hours, 20 μM MG-132 for 6 hours and 1 μM 
MLN4924 for 24 hours before cell lysed. The cells were lysed and 
analyzed by Western blotting with the Flag antibody. GAPDH was blotted 
as a loading control. 
 
 
6.1.2 Flag-GKAP1 accumulates upon Cycloheximide treatment 
Next, we tried to measure the half-life of the GKAP1 protein. To 
this end, HEK293T cells were transfected with Flag-GKAP1 and treated with 
cycloheximide alone or with cycloheximide and MLN4924 together before 
cell were lysed at the indicated times (0, 2, 4, 6 hours). As shown in Figure 
6.2, the Flag-GKAP1 protein concentration increased upon addition of 
cycloheximide both in the absence and presence of MLN4924. This result 
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further confirms that cycloheximide exerts a non-specific effect on the Flag-
GKAP1 protein. A recent study has indeed shown that cycloheximide can 
activate a number of signaling pathways, which can affect the half-life of 
cellular proteins (Dai et al., 2013). An accurate measurement of the GKAP1 
protein half-life would hence require pulse-chase analysis after metabolic 
labeling with [35S]-methionine. 
               
Figure 6.2 HEK293T cells were transfected with Flag-GKAP1 for 2 days 
and followed by the treatment of 40 μM cycloheximide (CHX) alone or 40 
μM cycloheximide (CHX) together with 1 μM MLN4924 for 2, 4, 6 hours as 
indicated at the top of each panel. The cells were lysed and analyzed by 
Western blotting using the Flag antibody.  
 
 
6.1.3 Flag-GKAP1 does not bind to β-TrCP 
To further investigate whether GKAP1 is an SCF substrate, binding 
of Flag-GKAP1 to the β-TrCP protein was examined. The FbxW class F-box 
protein β-TrCP is known to require phosphorylation of the serine residues in 
the DSGXX(X)S substrate recognition motif for substrate protein 
recruitment. Thus, we generated a Flag-GKAP1 S23A mutant in which the 
predicted phosphorylation site of the first serine residue in DSGXX(X)S has 
been mutated and measured the  binding of β-TrCP to wild type and mutant 
Flag-GKAP1 using co-immunoprecipitation assay. In the experiment in 
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Figure 6.3, cells were co-transfected with V5-β-TrCP and either empty 
vector, wild type Flag-GKAP1 or S23A mutant Flag-GKAP1, followed by 
immunoprecipition using Flag-agarose. There was significant non-specific 
binding of V5-β-TrCP in the absence of Flag-GKAP1 and only a slight 
increase in co-immunoprecipitated V5-β-TrCP in the presence of wild type 
Flag-GKAP1. This suggests that GKAP1 interacts at best weakly with β-
TrCP. Furthermore, the amount of V5-β-TrCP co-precipitated with the S23A 
mutant Flag-GKAP1 was similar compared to the wild type protein. This 
suggests that the GKAP1 protein is unlikely to be a substrate for β-TrCP-
dependent ubiquitination. However, it is possible that the specific interaction 
between GKAP1 and β-TrCP is not observed because GKAP1 is not 
phosphorylated under basal condition. Furthermore, we cannot rule out that it 
is a substrate for a cullin-dependent ligase different from SCFβ-TrCP. 
                             
Figure 6.3 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were 
subjected to Flag immunoprecipitation (IP). Immunoprecipitates and aliquots 




6.2.1 Flag-ACBD5 accumulates upon MLN4924 treatment  
In addition to GKAP1, acyl-CoA binding domain containing 5 
(ACBD5) has been reported as a potential new SCF substrate based on the 
study by Yen and Elledge, 2008. This protein is known to play a role in the 
transport and distribution of long chain acyl-Coenzyme (reviewed in 
Pippucci et al., 2011). ACBD5 may also be involved in megakaryocytes 
differentiation and platelet formation (Pippucci et al., 2011). It has been 
reported that mutation in ACBD5 can cause autosomal dominant 
thrombocytopenia. The ACBD5 protein also contains the DSGXX(X)S 
substrate recognition motif. Thus, we predict ACBD5 is a potential new SCF 
substrate. Similar to the previous approach, we first tried to validate whether 
Flag-ACBD5 is a potential SCF substrate by generating a Flag-ACBD5 
expression plasmid and transfecting the construct into HEK293T cells, 
followed by the MLN4924 treatment. As shown in the middle panel of 
Figure 6.4, one of the well-characterized SCF substrates, p27, served as a 
positive control. p27 was increased upon treatment with MLN4924 as well as 
with MG-132. Of note, MLN4924 increased p27 protein levels markedly 
more compared to MG-132. As expected, treatment with cycloheximide led 
to a dramatic decrease in the p27 protein concentration. The three inhibitors 
had similar effects on the Flag-ACBD5 protein compared to the positive 
control p27 (Upper panel Figure 6.4). Thus, Flag-ACBD5 protein levels were 
increased upon MLN4924 and MG-132 treatment, although less dramatic 
compared to p27. Thus, these results suggest that ACBD5 may be a potential 
new SCF substrate. 
! 111!
                                   
Figure 6.4 HEK293T cells transfected with Flag-ACBD5 were treated with 
1 μM MLN4924 for 24 hours, 20 μM MG-132 for 6 hours and 40μM 
cycloheximide (CHX) for 6 hours before cell lysed. The cell lysates were 





6.2.2 Flag-ACBD5 is insensitive to MLN4924  
Next, we investigated the half-life of ACBD. To this end, Flag-
ACBD5 was transfected into HEK293 cells and after two days, 
cycloheximide was added at time zero. Even though the ACBD5 protein 
abundance rapidly decreased upon treatment with cycloheximide, ACBD5 
protein decreased at a similar rate upon co-treatment with both 
cycloheximide and MLN4924 (Figure 6.5). This shows that this ACBD5 
protein is insensitive to the MLN4924 inhibitor. Thus, this suggests that it is 
unlikely to be a new SCF substrate.  
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Figure 6.5 HEK293T cell transfected with Flag-ACBD5 were treated with 
40μM cycloheximide (CHX) alone for 2, 4 and 6 hours or together 1 μM 
MLN4924 for 2, 4 and 6 hours before cell lysed. The cell lysates were 
analyzed by Western blotting with the Flag antibody.  
 
 
6.3.1 Tulp1-Flag accumulates slightly upon MLN4924 treatment  
Based on the study by Yen and Elledge (2008), Tulp1 has also been 
reported as a potential new SCF substrate. It has been reported that Tulp1 is 
associated with retinitis pigmentosa. Tulp1 mutations have been found in 
patients with nyctalopia or leber congenital amaurosis, a congenital form of 
severe vision impairment or blindness and early-onset RP (McKibbin et al., 
2010, Ajmal et al., 2012).  To test whether Tulp1 is a potential SCF 
substrate, we followed a similar approach as described above. As shown in 
Figure 6.6, the Tulp1-Flag protein level was only slightly increased upon 
MLN4924 treatment. In contrast, MLN4924 drug treatment resulted in a 
dramatic increase in p27 protein. Furthermore, treatment with MG-132 did 
not cause any increase in Tulp1-FLAG protein, but actually decreased 
protein levels slightly. Finally, inhibition of protein synthesis with 
! 113!
cycloheximide was without effect on Tulp1-Flag protein concentrations. 
Taken together, these results suggest that Tulp1 is a stable protein. 
Nevertheless, the Tulp1 protein contains two DSGXX(X)S substrate 
recognition motifs that are hypothesized to be recognized by β-TrCP. Thus, 
we further tested the binding of Tulp1 to β-TrCP. 
                                 
Figure 6.6 HEK293T cells transfected with Tulp1-Flag were treated with 
with 1 μM MLN4924 for 24 hours, 20 μM MG-132 for 6 hours and 40μM 
cycloheximide (CHX) for 6 hours before cell lysed. The cell lysates were 
analyzed by Western blotting with the indicated antibodies.  
 
 
6.3.2  Tulp1-Flag does not depend on the DSGXX(X)S recognition motif        
              to bind to β-TrCP  
The Tulp1 protein contains two DSGXX(X)S substrate recognition 
motifs. One is located at the extreme N-terminal and another one is located at 
the amino acid 471-476. These two substrate recognition motifs were 
predicted as the phosphorylation sites of the Tulp1 protein. Thus, to 
determine whether Tulp1 is regulated by the SCF β-TrCP complex, these two 
DSGXX(X)S substrate recognition motifs have to be deleted or mutated. 
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Here, a N-terminal truncated Tulp1-Flag S472A mutant was generated in 
which both predicted phosphorylation sites of the DSGXX(X)S substrate 
recognition motifs have been removed. We transfected wild type and the N-
terminal truncated Tulp1-Flag S472A mutant Tulp1-Flag into HEK293T 
cells and measured its binding to β-TrCP using co-immunoprecipitation 
assays. As shown in Figure 6.7, the N-terminal truncated Tulp1-Flag S472A 
mutant showed the same binding affinity to β-TrCP compared to wild type 
Tulp1-Flag. This suggests that the Tulp1 protein is not a β-TrCP-dependent 
ubiquitination substrate.  
                         
Figure 6.7 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were 
subjected to V5 immunoprecipitation (IP). Immunoprecipitates and aliquots 








6.4.1 SLBP accumulates upon MLN4924 treatment  
Next, we examined a further potential SCF substrate, Stem-loop 
binding protein (SLBP), which has also been reported by Yen and Elledge 
(2008), as putative SCF substrate. SLBP is essential in regulating cell cycle 
progression. It is critical for histone mRNA processing and transport into the 
cytoplasm (Sullivan et al., 2009). As shown in Figure 6.8, both endogenous 
and transfected SLBP-V5 proteins increased upon treatment with MLN4924. 
Thus, this result suggests that the stability of SLBP is regulated by a cullin-
based E3 ligase. Therefore, this result is consistent with SLBP protein being 
a potential SCF substrate. 
               
  
Figure 6.8 A. HEK293T cells were treated with 2 μM MLN4924 for 24 
hours. The cells were lysed and analyzed by Western blotting with SLBP 
antibody. B. HEK293T cells were transfected with V5-SLBP, followed by 2 
μM MLN4924 treatment for 24 hours and 20 μM MG-132 for 6 hours. The 
cells were lysed and analyzed by Western blotting with the V5 antibody. α-
tubulin was blotted as a loading control. 
 
6.4.2 SLBP accumulates upon Cyclin F siRNA knockdown treatment   
SLBP is essential in the cell cycle progression. It is regulated during 
S-phase of the cell cycle and destroyed at entry into G2 phase (Wagner et al., 
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2005). The SCF F-box protein Cyclin F has been reported to be involved in 
the degradation of cell-cycle regulators (D'Angiolella et al., 2013). The 
turnover of SLBP is cell cycle regulated (Whitfield et al., 2000). It is 
possible that the SCFCycllin F complex regulates the SLBP degradation. 
Thus, to test whether the SLBP degradation is dependent on the SCFCyclinF 
complex, we first determined the degradation rate of the endogenous SLBP 
protein in a Cyclin F siRNA knockdown assay. Based on Figure 6.9, 
knockdown of Cyclin F with two different siRNAs (Cyclin F siRNA #1 and 
#2) stabilized SLBP. Thus, the degradation rate of the SLBP protein was 
significantly slower in cycloheximide treated, Cyclin F knockdown cells 
compared to control siRNA cells. This suggests that Cyclin F knockdown 
increased the half-life of SLBP. Cyclin F siRNA #1 had a more prominent 
effect compared to Cyclin F siRNA2. This may be due to the fact that Cyclin 
F siRNA #1 knocked down Cyclin F more effectively than Cyclin F siRNA 
#2. Interestingly, cycloheximide treatment caused the appearance of a slower 
migrating band, likely representing phosphorylation events. However, the 
ratio between phosphorylated and unphosphorylated bands appeared similar 
between cyclin F knockdown and control cells. This suggests that 
phosphorylation does not regulate SLBP protein stability. Taken together 
with the previous result of the SLBP stabilization by MLN4924, we 
hypothesized that SLBP might be a potential new SCFCyclinF substrate.  
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Figure 6.9 HEK293T cells were transfected with Cyclin F siRNA#1, Cyclin 
F siRNA#2 and negative control for 3 days. This was then followed by the 
40 μM cycloheximide treatment for 0, 2 and 6 hours as indicated. The cells 
were lysed and analyzed by Western blotting with the SLBP antibody.  
 
 
6.4.3 Cyclin F does not regulate SLBP abundance in a cell cycle      
dependent manner   
It has been reported that SLBP is regulated during S-phase of the 
cell cycle and destroyed at entry into G2 phase (Wagner et al., 2005). Thus, 
we tried to determine whether the cell cycle dependent expression of the 
SLBP protein is regulated by cyclin F. To this end, a double thymidine block 
assay under a Cyclin F siRNA knockdown condition was performed to arrest 
the cells at the beginning of S phase. As shown in Figure 6.10, even though 
the abundance of SLBP was markedly increased under the Cyclin F siRNA 
knockdown condition, the rate of the decrease in SLBP abundance over time 
was not different compared to the negative control. Thus, this suggests that 
Cyclin F is unlikely to regulate the expression of SLBP in a cell cycle 
specific manner. 
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Figure 6.10 HEK293T cells were transfected with Cyclin F siRNA#1 and 
negative control for 3 days. After 24 hours of transfection, the cells were 
synchronized in G1/S phase with 2.5mM thymidine treatment for 16 hours. 
The cells were synchronized again as described after 72 hours of 
transfection. The cells were lysed at 0, 2, 4, 8, 10 hours after release from 
G1/S phase. Bottom, the bar graph represents the quantification of the 
SLBP/GAPDH protein abundance by densitometry. 
 
 
6.4.4 SLBP-V5 does not bind to HA-Cyclin F or Cul1  
To further examine whether SLBP is a SCFCyclinF substrate, we tried 
to determine whether SLBP interacts with Cyclin F and Cul1. To test this, 
SLBP-V5 and HA-Cyclin F proteins were transfected into HEK293T cells, 
followed by co-immunoprecipitation assay. As shown in Figure 6.11, HA-
Cyclin F did not bind to SLBP-V5 (compare binding of HA-Cyclin F to 
SLBP-V5 in lane 3 to non-specific binding of HA-Cyclin F in lane 2). Based 
on the Figure 6.12, weak binding of SLBP to Cul1 was detected (compare 
binding of Cul1 to SLBP-V5 in lane 2 to non-specific binding of Cul1 in lane 
1). Cotransfection of HA-Cyclin F increased binding of SLBP slightly (lane 
3). Taken together, the results suggest that there is no strong evidence that 
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Cyclin F functions as a substrate receptor to recruit SLBP for ubiquitination. 
Given the weak interaction of SLBP with Cul1, it is possible that SLBP 
ubiquitiation is mediated by a different F-box protein. Alternatively, given 
the strong stabilizing effect of the CRL inhibitor MLN4924, SLBP 
ubiquitination could also occur via a different cullin RING E3 ligase. 
  
Figure 6.11 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel cell lysates were subjected to 
V5 immunoprecipitation (IP). Immunoprecipitates and aliquots of lysates 
were analyzed by Western blotting with the indicated antibodies.  
 
        
Figure 6.12 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were 
! 120!
subjected to V5 immunoprecipitation (IP). Immunoprecipitates and aliquots 
of lysates were analyzed by Western blotting with the indicated antibodies.  
  
 
6.4.5 siRNA mediated knockdown of 41 different F-box does not lead to    
              SLBP accumulation 
To identify whether other F-box proteins are responsible for the 
SLBP degradation, we chose to use a knockdown approach. Out of the total 
approximately 70 mammalian F-box proteins, we excluded unlikely 
candidates with an expression limited to specific tissues or to non-nuclear 
cell compartments. 17 different F-box proteins were examined by a 
polytechnic attachment student (β-TrCP, Fbxw2, Fbxw4, Fbxw5, Fbxw7, 
Fbxw8, Fbxw10,(β-TrCP2, Fbxw12 or Fbxo35, Fbx15, Fbx16, Fbx17, 
Fbx112, Fbx114, Fbx116,(Fbx119, Fbxo3). For each F-box protein, two 
different siRNA oligonucleotides were used. Knockdown of these 17 F-box 
proteins did not result in a consistent increase in SLBP protein abundance. In 
further experiments, I used siRNAs targeting an additional 24 F-box proteins 
(two siRNAs per F-box protein). However, as shown in Figure 6.13, 
silencing of none of the 24 different F-box proteins led to significant SLBP 
stabilization. This suggests that SLBP may be degraded by other cullin 
ligases. 
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Figure 6.13 Hek293T cells were transfected with different F-box siRNA as 
indicated at the top of each panel for three days. The cells were lysed and 
analyzed by Western blotting with the SLBP antibody. α-tubulin was 
blotted as a loading control. 
 
 
6.4.6 Transfected dominant negative form of Cul1 (dnCul1-V5)    
increases SLBP protein expression slightly 
 
To identify whether a different CRL is responsible for the SLBP 
degradation, dominant negative forms of Cul1, Cul2, Cul3, Cul4 and Cul5 
were transfected into HEK293T cells. As shown in Figure 6.14, p27, which 
serves as a positive control, was accumulated upon MLN4924 treatment and 
transfection of the dominant negative form of Cul1 (dnCul1-V5) and 
dominant negative form of Ubc12 (dnUbc12-HA). SLBP protein increased 
slightly with different dominant negative cullin constructs, and more strongly 
with MLN4924 and duUbc12. The lower panels in Figure 6.14 show the 
densitometry quantification, representing the average of two independent 
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experiments. It is apparent in the lower panel that the known Cul1 substrate 
p27 shows the greatest accumulation with dnCul1, followed by dnUbc12 and 
MLN4924 treatment. If SLBP is also ubiquitinated by a Cul1 based E3 
ligase, a similar pattern of SLBP protein abundance would be expected. 
However, SLBP protein expression showed a smaller increase in dnCul1 
transfected compared MLN4924 treated and dnUbc12 transfected cells. This 
result indicates that SLBP ubiquitination is not (exclusively) mediated by a 
Cul1 based E3 ligase. Since a slight SLBP accumulation was observed with 
different dominant negative cullin proteins, it is possible that multiple CRLs 
contribute to the ubiquitination of SLBP. Alternatively, it is possible that 
SLBP degradation is dependent on the Nedd8 pathway (which is inhibited by 
MLN4924 and dnUbc12), but independent of CRLs. 
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Figure 6.14 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. Lysates were analyzed by 
Western blotting with the indicated antibodies. The results represent the 






6.4.7 V5-SLBP does not bind to endogenous Cul2, Cul3, Cul4, Cul5                
or Cul7 
To further confirm whether other CRLs are involved in SLBP 
ubiquitination, V5-SLBP was first transfected into HEK293T cells, followed 
by co-immunoprecipitation assays with V5 antibody to detect binding of 
endogenous cullin proteins. However, as shown in Figure 6.15, none of the 
V5-SLBP protein was found to bind to endogenous Cul2, Cul3, Cul4, Cul5 
or Cul7 in a specific manner. This suggests that ubiquitination of SLBP is 
not mediated by these CRLs 
                      
Figure 6.15 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were 
subjected to V5 immunoprecipitation (IP). Immunoprecipitates and aliquots 
of lysates were analyzed by Western blotting with the indicated antibodies. 
 
 
6.4.8 V5-SLBP does not bind to Cdh1 
 Inhibition of CRLs can lead to the stabilization of specific proteins 
via indirect mechanisms. For instance, inhibition of SCFβ-TrCP results in 
stabilization of the Emi1 protein, an endogenous inhibitor of the anaphase-
promoting complex/cyclosome (APC/C) Cdh1 E3 ubiquitin ligase (Moshe et 
al., 2004, reviewed in HC Vodermaier, 2004). Furthermore, inhibition of 
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CRL function is also associated with cell cycle delay. Our laboratory has 
recently shown the MLN4924 induced stabilization of the cdc6 protein is due 
to cell cycle arrest, leading to delayed cdc6 ubiquitination via APC/CCdh1 
(Tan and Hagen, 2013). Hence, we next tried to determine whether the 
APC/CCdh1 E3 ubiquitin ligase is involved in regulating the SLBP protein. To 
test this, we tried to measure binding between SLBP and Cdh1 using co-
immunoprecipitations.  As shown in Figure 6.16, Cdh1-Myc did not bind to 
SLBP in a specific manner (compare binding of Cdh1-Myc to V5-SLBP in 
lane 2 to non-specific binding of Cdh1-Myc in lane 1). This suggests that the 
APCCdh1 complex is unlikely to play a role in regulating SLBP degradation. 
                                  
Figure 6.16 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were 
subjected to V5 immunoprecipitation (IP). Immunoprecipitates and aliquots 
of lysates were analyzed by Western blotting with the indicated antibodies. 
 
 
6.4.9 Cycle Inhibiting Factor causes SLBP accumulation 
Based on our previous data, inhibition of the neddylation pathway 
using MLN4924 or dnUbc12 has been shown to lead to the accumulation of 
SLBP. Given that CRLs appear not to be involved in SLBP ubiquitination, it 
is possible that SLBP ubiquitination and degradation involves a Nedd8 
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dependent, but cullin independent mechanism. To obtain further evidence for 
a Nedd8 dependent mechanism, we tested whether the human Nedd8-
specific protease NEDP1 or Cycle Inhibiting Factor (Cif) from Burkholderia 
pseudomallei can regulate the abundance of the SLBP expression. NEDP1 is 
a NEDD8-specific deneddylase which is responsible to remove Nedd8 
conjugated to substrate proteins (Gan-Erdene et al., 2003). NEDP1 has been 
shown to preferentially deneddylate non-cullin proteins in vivo (Chan et al., 
2008). CIF has been shown to block the cell cycle at both the G1/S phase and 
the G2/M phase (Jubelin et al., 2010). This effect is due to deamidation of 
the Nedd8 protein at Gln40, leading to loss of function of Nedd8. To test 
whether these two proteins can regulate the SLBP expression, NEDP1-Flag 
and Flag-CIF were transfected into HEK293T cells and the abundance of 
SLBP was measured using western blotting. As shown in Figure 6.17, the 
abundance of SLBP was markedly increased in Flag-CIF transfected cells 
whereas NEDP1-Flag had no significant effect. 
                                    
 
Figure 6.17 HEK293T cells were transfected with expression constructs for 
the proteins indicated at the top of each panel. The cell lysates were analyzed 




   Discussion 
 The SCF (Skp1, Cullins, F-box proteins) E3 ubiquitin ligase is 
known to play an essential role in regulating the ubiquitination of numerous 
regulatory proteins. The SCF complex consists of Cul1, Skp1 and one of the 
F-box proteins. Among the F-box proteins, some are proto-oncogenes that 
target tumor suppressor protein for degradation, whereas others are tumor-
suppressors that are responsible for the degradation of proto-oncoproteins. 
For instance, one oncogenic example of the SCF F-box proteins is Skp2. It 
plays an important role to promote the degradation of cyclin-dependent 
kinase inhibitor p27(kip1) (p27). Hence, overexpression of Skp2, as 
frequently observed in cancer, results in downregulation of p27, leading to 
increased cellular proliferation. .  
Since the SCF complex targets various regulatory proteins for 
degradation, it has been recognized as a potential therapeutic target in cancer. 
The most well-known small molecule inhibitor of the ubiquitin proteasome 
system (UPS) is bortezomib (Richardson et al., 2005). It is a general 
proteasome inhibitor and hence inhibits the degradation of SCF substrates as 
well as substrates of all other E3 ubiquitin ligases. Bortezomib has been used 
for the treatment of multiple myeloma and mantle cell lymphoma. 
Bortezomib has been shown to target the nuclear factor-kappa B (NFκB) 
pathway in multiple myeloma cells. It blocks the degradation of the SCFβ-TrCP 
substrate Inhibitor of kappa B alpha (IκBα) and thus abolishes the NFκB 
transcriptional activity. Therefore, this inhibits the functions of NFκB such 
as cell invasion, proliferation, and survival (Yang et al., 2008; Markovina et 
al., 2008).  Bortezomib has been proved to be a potential and useful cancer 
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therapeutic agent in multiple myeloma. Recently, there have been efforts to 
target Cullin E3 ubiquitin ligases including SCF specifically and selectivity. 
The most prominent example of a potent and specific inhibitor of all CRLs is 
MLN4924, a small molecule inhibitor of the Nedd8-activating enzyme. It 
targets all CRLs including SCF E3 ubiquitin ligases via blocking cullin 
neddylation. Therefore, it can cause the accumulation of SCF substrates and 
has been shown to suppress the growth of tumor cells by inducing apoptosis. 
In addition, a number of specific SCF inhibitors have been identified. Small-
molecule enhancer of rapamycin 3 (SMER3), an inhibitor of the SCFMet30 
ubiquitin ligase, has been shown to inhibit the SCFMet30 activity by destroying 
the binding of the F-box subunit Met30 to the SCF component (Aghajan et 
al., 2010). For the SCFCdc4 complex, a biplanar dicarboxylic acid compound, 
SCF-12, has been revealed to prevent the SCFCdc4 substrate binding and 
ubiquitnation (Orlicky et al., 2010). It has also been shown that the Skp2-
inhibitor named as compound #25 inhibits SCFSkp2 activity by destroying the 
Skp2-Skp1 interaction (Chan et al., 2013). 
In this study, we tried to identify novel SCF substrates that may be 
involved in cancer. Based on candidate SCF substrates identified by global 
protein stability profiling (Yen and Elledge, 2008), we selected GKAP1, 
ACBD5 and Tulp1 for evaluation. Given the presence of a β-TrCP 
recognition motif in these proteins, we hypothesized that these proteins are 
substrates for the SCFβ-TrCP E3 ligase. Based on our results, the abundance of 
the GKAP1 and ACBD5 proteins accumulated after the treatment of 
MLN4924 based on our results. Thus, this suggests that both the GKAP1 and 
ACBD5 proteins are potential novel Cullin1 substrates. However, GKAP1 
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did not show to bind to the β-TrCP in a co-immunoprecipitation assay. Thus, 
this suggests that GKAP1 is unlikely as a SCF novel substrate. ACBD5 
however also proved insensitive to MLN4924 treatment when investigating 
the ACBD5 half-life, suggesting it is not a potential SCF substrate.  For the 
Tulp1 protein, its abundance did not increase after the MLN4924 treatment. 
Although Tulp1 contains two β-TrCP recognition motifs, it was however 
shown to bind to β-TrCP in a DSGXX(X)S motif independent manner. 
Therefore, our results indicate that these proteins are unlikely to be regulated 
by the SCF complex. Our findings illustrate the importance of functional 
validation of the protein stability profiling data. 
We also studied the mechanism of SLBP degradation to confirm the 
protein as a potential SCF substrate (Yen and Elledge, 2008) and to identify 
the involved F box protein. Upon inhibition of cullin ligases via MLN4924, 
the abundance of the SLBP protein was increased. Inhibiting CRL function 
with dnUbc12 caused even more pronounced stabilization of SLBP. Based 
on our results, SLBP also appeared to be stabilized when the F-box protein 
Cyclin F was silenced with siRNA. Since SLBP and Cyclin F are known to 
be involved in cell cycle regulation (Whitfield et al., 2000, D’Angiolella et 
al., 2010), we hypothesized that Cyclin F may be involved in the SLBP 
ubiquitination. However, Cyclin F did not appear to regulate SLBP protein 
abundance in a cell cycle dependent manner and did not bind to SLBP. 
Therefore, SLBP is unlikely to be regulated by the SCFCyclin F complex. We 
obtained some evidence that SLBP is partially regulated via the SCF 
complex. Firstly, dnCul1-V5 slightly increased SLBP. Secondly, SLBP 
appeared to bind weakly to Cul1. However, in an siRNA knockdown screen 
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of 42 different F-box proteins, SLBP did not appear to be stabilized upon 
silencing of any of the F-box proteins. These results suggest that the SCF 
complex may not be involved in playing a major role in SLBP ubiquitination. 
Furthermore, we found that in a screen using dominant-negative forms of all 
cullin proteins, inhibition of all individual CRLs caused no or only small 
increases in SLBP abundance. We were also unable to detect robust binding 
of SLBP to specific cullin proteins. This indicates that CRLs are unlikely to 
play a dominant role in mediating SLBP ubiquitination. Notwithstanding, 
based on the SLBP stabilization with MLN4924 and dnUbc12, a functional 
Nedd8 pathway is likely to be required for SLBP degradation. This 
conclusion is supported by the finding that the B. pseudomallei virulence 
factor Cif, which inactivates Nedd8 through deamidation, also causes 
stabilization of SLBP. Hence, we propose that SLBP ubiquitination and 
degradation is dependent on a functional Nedd8 pathway, but largely 
independent of CRL function. 
It is known that SLBP is playing an important role in cell cycle 
progression. Cells that are depleted of SLBP accumulated in S phase and 
progress slowly through S phase (Wagner et al., 2005). It has been revealed 
that SLBP is essential for histone mRNA processing and transport into the 
cytoplasm (Sullivan et al., 2009). Without histone, cell cycle cannot progress 
through G2 phase. Thus, SLBP may provide an alternative way in preventing 
the cancer cell growth by controlling the histone mRNA processing. 
Therefore, it is important to understand how the SLBP protein is regulated by 
the SCF complex and the Nedd8 modification. This may help to elucidate the 
cell cycle dependent regulation of histone mRNA processing. 
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7.0 General Conclusions  
In the past several years, enormous amount of research to elucidate 
the function of CRLs and CSN has been performed and great progress has 
been achieved. In this study, we aimed to address a number of specific 
questions relating to the regulation of CRLs by CSN and Nedd8 in vivo. It 
has been suggested that CRLs undergo rapid cycles of neddylation and 
deneddylation in vivo (Cope and Deshaies, 2003; Bosu and Kipreos, 2008; 
Wei et al., 2008). Finding from our studies support the hypothesis that the 
neddylation and denddylation of cullins in vivo is dynamic. Recent studies 
have shown that CRL substrates upon biding displace CSN through steric 
effects (Enchev et al., 2012). This mechanism likely accounts for the 
dynamic in vivo regulation of cullin neddylation. Our findings of preferential 
binding of CSN to the active, neddylated form of CRLs helps to explain the 
rapid deneddylation that is observed after substrate dissociation. Our results 
also indicate that CAND1 is not involved in regulating cullin deneddylation 
and that CSN binding to Cul1 does not regulate the CAND1-Cul1 
interaction. These findings suggest that CAND1 likely does not function to 
sequester inactive CRLs. Indeed, recent studies have shown that CAND1 
functions as an exchange factor for binding of new F-box proteins to the SCF 
complex (Pierce et al., 2013).  
We also pursued studies to characterize the mechanism of Cul3 E3 
ubiquitin ligase dimerization. It has been suggested that CRL3 dimerization 
is important for recruitment of various substrates and for mediating ubiquitin 
transfer. CRL dimerization is likely of importance to accommodate changes 
! 132!
in substrate positioning during extension of the polyubiquitin chain. We 
found that the majority of the cellular Cul3 proteins exist as dimers or 
multimers, providing support for an important role of this regulatory 
mechanism. In our study, we addressed the mechanism of Cul3 dimerization. 
We found that homodimerization of the BTB substrate receptor proteins is 
essential in mediating the CRL3 complex dimerization. This contradicts with 
a previously proposed model by Wimuttisuk and Singer, 2007. Our findings 
also suggest that Cul3 C-terminus is not important for the Cul3 dimerization 
and that Cul3 dimerization is independent of Cul3 neddylation. Thus, the 
mechanism of CRL3 dimerization is similar to that of other CRLs, notably 
the SCF complex, where dimerization is mediated via a dimerization motif 
(D-domain) identified in a number of F-box protein substrate receptors.  
We subsequently tried to identify novel cellular substrates of the 
SCFβ-TrCP E3 ligase that may be involved in cancer. Three potential 
substrates, Gkap1, ACBD5 and Tulp1, contain a β-TrCP recognition motif 
and were selected from the list of identified SCF substrate by Yen and 
Elledge (2008) to be evaluated using the MLN4924 inhibitor. Although the 
Gkap1 protein was accumulated after MLN4924 treatment, it showed no 
binding to β-TrCP. For the ACBD5 protein, we found that it is insensitive to 
the MLN4924 inhibitor. Our results also showed that the Tulp1 protein binds 
to β-TrCP. However its binding to β-TrCP is independent of the β-TrCP 
recognition motif (the DSGXX(X)S motif). We next selected the SLBP 
protein based on candidate SCF substrates identified by global protein 
stability profiling and tried to determine whether it is a novel substrate for 
the SCF E3 ligase. Our results show that SLBP ubiquitination is likely 
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independent of the SCF complex and other Cullin E3 ubiquitin ligases, but 
dependent on a functionsl Nedd8 pathway. The SLBP protein is important in 
regulating the cell cycle progression. It has been reported that SLBP is 
critical for histone mRNA processing and nuclear export (Wagner et al., 
2005). Thus, it is essential to study the mechanism through which the Nedd8 
pathway regulates SLBP protein stability. This may help to understand the 
involvement of SLBP in cell cycle regulation. Our results also suggest that 
the neddylation pathway plays important roles in regulating cellular 
functions other than CRL dependent substrate ubiquitination. Indeed, 
evidence has been provided that in addition to cullins, many other cellular 
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